CN1155615C - Human protein with cancer cell growth suppressing function and its coding sequence - Google Patents

Abstract

The present invention discloses a novel human protein with the function of inhibiting cancer, polynucleotide for encoding the polypeptide and a method for preparing the polypeptide by a recombinant technology. The present invention also discloses a method of using the polypeptide to treat various diseases, such as cancers. The present invention also discloses an antagonist of the polypeptide and a therapeutic effect thereof. The present invention also discloses the application of the polynucleotide for encoding the human protein with the function of inhibiting cancer.

Description

New people's albumen and encoding sequence thereof with anticancer growth function

The invention belongs to biological technical field, specifically, the present invention relates to the proteic polynucleotide of people that new coding has cancer suppressing function, and the polypeptide of this polynucleotide encoding.The invention still further relates to the purposes and the preparation of these polynucleotide and polypeptide.

The research of people's gene group is international focus at present, removes human chromosome DNA large scale sequencing, outside the method for expressed sequence order-checking (EST), also lacks the screening that begins from function and has the high-throughout method of functional gene.

Cancer is one of principal disease of harm humans health.In order to treat effectively and prophylaxis of tumours, people more and more pay close attention to genetic treatment of tumor at present.Therefore, this area presses for people's albumen and the agonist/inhibitor thereof that development research has cancer suppressing function.

The purpose of this invention is to provide the new people's protein polypeptide of a class with cancer suppressing function with and fragment, analogue and derivative.

Another object of the present invention provides the polynucleotide of these polypeptide of coding.

Another object of the present invention provides the method for these polypeptide of production and the purposes of this polypeptide and encoding sequence.

In a first aspect of the present invention, novel isolated protein polypeptide with cancer suppressing function is provided, and it comprises the polypeptide of the aminoacid sequence with the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ IDNO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29; Or its conservative property variation polypeptide or its active fragments or its reactive derivative.

Preferably, this polypeptide is the polypeptide with aminoacid sequence of the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ IDNO:23, SEQ ID NO:26, SEQ ID NO:29.

In a second aspect of the present invention, a kind of isolating polynucleotide are provided, it comprises a nucleotide sequence, and this nucleotide sequence is shown at least 85% homogeny with a kind of nucleotides sequence that is selected from down group: the polynucleotide of the above-mentioned protein polypeptide with cancer suppressing function of (a) encoding; (b) with polynucleotide (a) complementary polynucleotide.Preferably, the polypeptide of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:2, SEQID NO:5, SEQ ID NO:8, SEQ IDNO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29.More preferably, the sequence of these polynucleotide is selected from down group: coding region sequence or the full length sequence of SEQ ID NO:3, SEQ ID NO:6, SEQID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30.

In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.

In a fourth aspect of the present invention, the preparation method who prepares the polypeptide of the protein-active with cancer suppressing function is provided, this method comprises: (a) have under the proteic condition of cancer suppressing function suitable the expression, cultivate the above-mentioned host cell that is transformed or transduce; (b) from culture, isolate the polypeptide of protein-active with cancer suppressing function.

In a fifth aspect of the present invention, provide and above-mentioned protein polypeptide specificity bonded antibody with cancer suppressing function.The nucleic acid molecule that can be used for detecting also is provided, and it contains, and continuous 10 Nucleotide are to full length nucleotide in the above-mentioned polynucleotide, and preferably it contains the about 10-800 of a successive Nucleotide.

In a sixth aspect of the present invention, a kind of pharmaceutical composition is provided, it contains the protein polypeptide and the pharmaceutically acceptable carrier with cancer suppressing function of the present invention of safe and effective amount.These pharmaceutical compositions can be treated illnesss such as cancer and cellular abnormality propagation.

Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.

The present invention adopts large-scale cDNA clone transfection cancer cells, has on the basis of cancer suppressing action in acquisition, proves new gene through order-checking, further obtains full length cDNA clone.DNA transfection evidence, the albumen with cancer suppressing function of the present invention has the effect that suppresses clone's formation to cancer cells (liver cancer cell), and its inhibiting rate is more than 50% or 50%.

As used herein, " isolating " is meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.

As used herein, " isolating albumen or polypeptide with cancer suppressing function " is meant that the protein polypeptide with cancer suppressing function is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can have the albumen of cancer suppressing function with the purified technology of protein purifying of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.Purity with protein polypeptide of cancer suppressing function can be used amino acid sequence analysis.

Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.

The present invention also comprises the proteic fragment of the people with cancer suppressing function, derivative and analogue.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep natural identical biological function or the active polypeptide of people's albumen with cancer suppressing function of the present invention basically.Polypeptide fragment of the present invention, derivative or analogue can be that (i) has one or more conservative or substituted polypeptide of non-conservation amino-acid residue (preferred conservative amino acid residue), and the amino-acid residue of such replacement can be also can not encoded by genetic code, or (ii) in one or more amino-acid residues, has a polypeptide of substituted radical, or (iii) mature polypeptide and another compound (such as the compound that prolongs the polypeptide transformation period, polyoxyethylene glycol for example) merge formed polypeptide, or (iv) additional aminoacid sequence is fused to this peptide sequence and the polypeptide that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying).According to the instruction of this paper, these fragments, derivative and analogue belong to the known scope of those skilled in the art.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.Be example with PP7027 albumen (in this application, its clone numbering is adopted in proteinic name), the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:3 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that in the present invention coding has the protein of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ IDNO:3.Be example with PP7059 albumen (in this application, its clone numbering is adopted in proteinic name), the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:6 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that in the present invention coding has the protein of SEQ ID NO:5, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:6.Have the albumen of cancer suppressing function for other, can the rest may be inferred.Have the albumen of cancer suppressing function for other, can the rest may be inferred.

The polynucleotide of encoding mature polypeptide comprise: the encoding sequence of an encoding mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

Term " polynucleotide of coded polypeptide " can be the polynucleotide that comprise this polypeptide of encoding, and also can be the polynucleotide that also comprise additional code and/or non-coding sequence.

The invention still further relates to the varient of above-mentioned polynucleotide, its coding has the polypeptide of identical aminoacid sequence or fragment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.

The invention still further relates to and above-mentioned sequence hybridization and two sequences between have at least 50%, preferably at least 70%, the polynucleotide of at least 80% homogeny more preferably.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time is added with denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function (is example with PP7027 albumen) and activity with the mature polypeptide shown in the SEQ IDNO:2.

The invention still further relates to nucleic acid fragment with above-mentioned sequence hybridization.As used herein, the length of " nucleic acid fragment " contains 15 Nucleotide at least, better is at least 30 Nucleotide, is more preferably at least 50 Nucleotide, preferably more than at least 100 Nucleotide.The amplification technique (as PCR) that nucleic acid fragment can be used for nucleic acid has the proteic polynucleotide of cancer suppressing function to determine and/or to separate to encode.

Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.

Dna sequence dna of the present invention can obtain with several method.For example, with hybridization technique DNA isolation well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homology nucleotide sequence and 2) antibody screening of expression library to be to detect the dna fragmentation of the clone with common structure feature.

The proteic specific DNA fragment sequence that coding has cancer suppressing function produces also and can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of required polypeptide.

In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.When the whole aminoacid sequence of the polypeptide product of needs was known, the direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.When if required amino acid whose whole sequence is not known, the direct chemical of dna sequence dna is synthetic to be impossible, and the method for selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.

Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) function of marker gene occurs or forfeiture; (3) mensuration has the level of the proteic transcript of cancer suppressing function; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.

In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 15 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, the length of probe within 2kb, preferably is within the 1kb usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene DNA sequence information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.

In (4) kind method, detect the protein product of protein gene expression and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc. with cancer suppressing function.

Use method (Saiki, the et al.Science 1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to obtain the cDNA of total length from the library, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.

The gene of the present invention that obtains as mentioned above, perhaps the available ordinary method of mensuration of the nucleotide sequence of various dna fragmentations etc. such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467).This class nucleotide sequencing is available commercial sequencing kit etc. also.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.

The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered with carrier of the present invention or albumen coded sequence with cancer suppressing function, and the method that produces polypeptide of the present invention through recombinant technology.

Recombinant DNA technology (Science, 1984 by routine; 224:1431), can utilize polymerized nucleoside acid sequence of the present invention to can be used to express or produce the protein polypeptide with cancer suppressing function of reorganization.In general following steps are arranged:

(1). have the proteic polynucleotide of people (or varient) of cancer suppressing function with coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;

(2). the host cell of in suitable medium, cultivating;

(3). separation, protein purification from substratum or cell.

Among the present invention, the people's albumen polynucleotide sequence with cancer suppressing function can be inserted in the recombinant expression vector.Term " recombinant expression vector " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carriers.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on T7 of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier can be used.A key character of expression vector is to contain replication orgin, promotor, marker gene and translation controlling elements usually.

Method well-known to those having ordinary skill in the art can be used to make up and contains people's encoding histone dna sequence dna with cancer suppressing function and suitable transcribing/the translate expression vector of control signal.These methods comprise (Sambroook, et al.Molecular Cloning, a Laboratory Manual, coldSpring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; Lambda particles phage P _LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in protokaryon or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site and the transcription terminator that translation initiation is used.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance.

Comprise the carrier of above-mentioned suitable dna sequence dna and suitable promotor or control sequence, can be used to transform appropriate host cell, so that it can marking protein.

Host cell can be a prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; The bacterial cell of Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; The insect cell of fruit bat S2 or Sf9; The zooblast of CHO, COS or Bowes melanoma cells etc.

When polynucleotide of the present invention are expressed in higher eucaryotic cells, be enhanced if will make to transcribe when in carrier, inserting enhancer sequence.Enhanser is the cis acting factor of DNA, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.

Persons skilled in the art all know how to select appropriate carriers, promotor, enhanser and host cell.

Can carry out with routine techniques well known to those skilled in the art with the recombinant DNA transformed host cell.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results ₂Method is handled, and used step is well-known in this area.Alternative is to use MgCl ₂If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, conventional mechanical method such as microinjection, electroporation, liposome packing etc.

The transformant that obtains can be cultivated with ordinary method, expresses the polypeptide of coded by said gene of the present invention.According to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.

Recombinant polypeptide in the above methods can wrap by in cell, extracellular or on cytolemma, express or be secreted into the extracellular.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.The example of these methods includes, but are not limited to: conventional renaturation handles, with protein precipitant handle (salt analysis method), centrifugal, the broken bacterium of infiltration, superly handle, the combination of super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.

The people's albumen or the polypeptide with cancer suppressing function of reorganization are of use in many ways.These purposes include, but is not limited to: directly have the disease due to the low or forfeiture of the protein function of cancer suppressing function as pharmacological agent and be used to screen and promote or antagonism has antibody, polypeptide or other part of the protein function of cancer suppressing function.For example, antibody can be used for activating or suppressing to have the proteic function of people of cancer suppressing function.The people's protein screening peptide library that has a cancer suppressing function with the reorganization of expressing can be used for seeking the peptide molecule that can suppress or stimulate the people's protein function with cancer suppressing function of therapeutic value.

The present invention also provides screening of medicaments to improve (agonist) or check the method that (antagonist) has the proteic medicament of people of cancer suppressing function to identify.Agonist improves the biological function such as stimulate cellular proliferation of the people's albumen with cancer suppressing function, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can be in the presence of medicine, the proteic film preparation of people that mammalian cell or expression is had cancer suppressing function is cultivated with the people's albumen with cancer suppressing function of mark.Measure the medicine raising then or check this interactional ability.

The proteic antagonist of people with cancer suppressing function comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The proteic antagonist of people with cancer suppressing function can and be eliminated its function with the people's protein binding with cancer suppressing function, or suppresses to have the proteic generation of people of cancer suppressing function, or combines with the avtive spot of polypeptide and to make polypeptide can not bring into play biological function.The proteic antagonist of people with cancer suppressing function can be used for therepic use.

In screening during as the compound of antagonist, the albumen that can have a cancer suppressing function adds during bioanalysis measures, and determines by measuring albumen and the interaction between its acceptor that compounds affect has cancer suppressing function whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.

Polypeptide of the present invention can be directly used in disease treatment, for example, and various malignant tumours and cellular abnormality propagation etc.

Polypeptide of the present invention, and fragment, derivative, analogue or their cell can be used as antigen to produce antibody.These antibody can be polyclone or monoclonal antibody.Polyclonal antibody can obtain by the method with this polypeptide direct injection animal.The technology of preparation monoclonal antibody comprises hybridoma technology, three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.

Can be with polypeptide of the present invention and antagonist and suitable pharmaceutical carrier combination back use.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.

The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.

Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Albumen with cancer suppressing function comes administration with the amount that treats and/or prevents concrete indication effectively.The proteic amount with cancer suppressing function and the dosage range that are applied to the patient will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.

The proteic polynucleotide of people with cancer suppressing function also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating since have that the proteic nothing of cancer suppressing function is expressed or the proteic expression with cancer suppressing function of unusual/non-activity due to cell proliferation, growth or metabolic disturbance.The albumen with cancer suppressing function that the gene therapy vector (as virus vector) of reorganization can be designed to express variation is to suppress endogenic protein-active with cancer suppressing function.For example, a kind of albumen with cancer suppressing function of variation can be the albumen with cancer suppressing function that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the protein expression with cancer suppressing function or the disease of active caused by abnormal.Deriving from the expression vector of virus such as protein gene that retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for having cancer suppressing function is transferred in the cell.The method that structure carries the recombinant viral vector of the protein gene with cancer suppressing function is found in existing document (Sambrook, et al.).The people protein gene of reorganization with cancer suppressing function can be packaged in the liposome and be transferred in the cell in addition.

Suppress to have cancer suppressing function people's protein mRNA oligonucleotide (comprising sense-rna and DNA) and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.

Polynucleotide imports tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.

Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carry out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension.

The present invention also provides the antibody at the people's proteantigen determinant with cancer suppressing function.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.

The anti-proteic antibody of people with cancer suppressing function can be used in the immunohistochemistry technology, detects the people's albumen with cancer suppressing function in the biopsy specimen.

With the also available labelled with radioisotope of the protein bound monoclonal antibody of the people with cancer suppressing function, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.

Antibody among the present invention can be used for treating or prevents and the relevant disease of people's albumen with cancer suppressing function.The antibody that gives suitable dosage can stimulate or block proteic generation of the people with cancer suppressing function or activity.

Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As have cancer suppressing function people's albumen high-affinity monoclonal antibody can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing the cell of the people's protein positive with cancer suppressing function.

Available people's albumen or the polypeptide immune animal of the production of polyclonal antibody with cancer suppressing function, as rabbit, mouse, rat etc.Multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.

Have cancer suppressing function people's protein monoclonal antibody can with hybridoma technology production (Kohler and Milstein.Nature, 1975,256:495-497).With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.PatNo.4946778) also can be used for producing the anti-proteic single-chain antibody of people with cancer suppressing function.

Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with the protein bound peptide molecule of the people with cancer suppressing function obtains.During screening, must carry out mark to people's protein molecular with cancer suppressing function.

The invention still further relates to quantitatively and detection and localization has the diagnostic testing process of people's protein level of cancer suppressing function.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The people's protein level that is detected in the test with cancer suppressing function, the disease that can have the importance of people's albumen in various diseases of cancer suppressing function with laying down a definition and be used to diagnose albumen to work with cancer suppressing function.

Proteic polynucleotide with cancer suppressing function can be used for having the diagnosis and the treatment of the protein related diseases of cancer suppressing function.Aspect diagnosis, the proteic polynucleotide with cancer suppressing function can be used for detecting have cancer suppressing function proteic expression whether or under morbid state, have an abnormal exprssion of cancer suppressing function.As the protein D NA sequence with cancer suppressing function can be used for the hybridization of biopsy specimen is had with judgement the proteic abnormal expression of cancer suppressing function.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out RNA-polymerase chain reaction (RT-PCR) amplification in vitro with the special primer of the albumen with cancer suppressing function and also can detect proteic transcription product with cancer suppressing function.

The sudden change that detection has the protein gene of cancer suppressing function also can be used for diagnosing the relevant disease of albumen with cancer suppressing function.Form with protein mutation of cancer suppressing function comprises that to have point mutation that the protein D NA sequence of cancer suppressing function compares, transposition, disappearance, reorganization and other any unusual etc. with normal wild type.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.

Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.

In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.

The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).

The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manual of BasicTechniques, Pergamon Press, New York (1988).

In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, Mendelian Inheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.

Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.

Pyrenoids thuja acid full length sequence or its fragment with cancer suppressing function of the present invention can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention about nucleotide sequence, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.

In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.

In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually, by first synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.

At present, can be fully come the dna sequence dna of code book invention albumen (or its fragment, or derivatives thereof) by chemosynthesis.This dna sequence dna can be introduced then in the various dna moleculars (as carrier) and cell in this area.In addition, also can will suddenly change and introduce in the protein sequence of the present invention by chemosynthesis.

In addition, because the albumen with cancer suppressing function of the present invention has the natural acid sequence that is derived from the people, therefore, compare with the albumen of the same clan that derives from other species, estimate to have higher active and/or lower side effect (for example in the intravital immunogenicity of people lower or do not have) being applied to man-hour.

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold Spring Harbor LaboratoryPress, 1989) condition described in, or the condition of advising according to manufacturer.

The acquisition of embodiment 1:cDNA gene and the restraining effect that the cancer cells clone is formed

PP7027, PP7059, PP7130, PP7298, PP7425, PP7651, PP7664, PP7827, PP7882 and PP8038 obtain by making up the human placenta cDNA library with ordinary method.Get the placenta tissue at 3,6,10 monthly ages, (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.Make up the cDNA library of above-mentioned mRNA with pCMV-script TMXR cDNA library construction test kit (Stratagene company).Wherein ThermoScript II is used MMLV-RT-Superscript II (GIBCO BRL) instead, and reverse transcription reaction carries out at 42 ℃.Transform XL 10-Gold recipient cell, obtained 1 * 10 ⁶The cDNA library of cfu/ μ g cDNA titre.The first round is picking cDNA clone at random, is probe with high abundance cDNA clone with the cDNA clone who has proved cancer inhibitor cell growth function thereafter, screening by hybridization cDNA library, weak positive and negative clone of picking.With Qiagen 96 orifice plate plasmid extraction test kits, carry out the extraction of plasmid DNA by shop instruction.Plasmid DNA and empty carrier transfection simultaneously hepatoma cell line 7721.After the 100ng DNA alcohol precipitation drying, add 6 μ l H ₂Transfection is treated in the O dissolving.Add 0.74 μ l liposome and 9.3 μ l serum-free mediums in every part of DNA sample, behind the mixing, room temperature was placed 10 minutes.Add 150 μ l serum-free mediums in every pipe, divide equally and add 3 holes and grow in 7721 cells of 96 orifice plates, placed 2 hours for 37 ℃, every hole adds 50 μ l serum-free mediums again, 37 ℃ 24 hours.Every hole is changed 100 μ l and is trained liquid entirely, 37 ℃ 24 hours, change the full training liquid 100 μ l that contain G418,37 ℃ 24～48 hours, the limit is observed, the training liquid that G418 concentration does not wait is changed on the limit.After about 2～3 times, there is the clone to form up to the microscopy cell, counting.Find that above clone has the cell clone of inhibition formation effect, the result is as shown in the table.

CDNA clone's transfectional cell (7721) clone formation situation

CDNA clones title	CDNA clones number (three repetitions)	Empty carrier clone number (three repetitions)
			PP7027 PP7059 PP7130 PP7298 PP7425 PP7651 PP7664 PP7827 PP7882 PP8038	12 7 14 15 18 13 9 12 32 6 5 7 10 15 12 14 11 17 21 14 16 0 0 0 1 2 0 4 7 3	63 58 62 48 38 35 56 50 47 48 38 35 30 32 34 30 32 34 30 32 34 26 29 30 26 29 30 48 38 35

Above-mentioned cDNA clone is adopted two deoxidation cessation method, on the ABI377 automatic dna sequencer, measure the nucleotide sequence of the nearly 500bp of one end.After the analysis, be defined as novel gene cloning, carry out the other end order-checking, do not obtain full length cDNA sequence yet, the design primer checks order once more, up to obtaining full length sequence (SEQ ID NO:1,4,7,10,13,16,19,22,25,28).

Embodiment 2: PCR obtains full-length gene from placenta cDNA:

Get the placenta tissue at 3,6,10 monthly ages, (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.With MMLV-RT-Superscript II (GIBCO BRL), ThermoScript II is carried out reverse transcription reaction at 42 ℃, obtains placenta cDNA.Utilize the different primer of commentaries on classics (as shown in the table) of each gene, by 97 ℃ of 3 minutes, 1 circulations; 94 ℃ 30 seconds → 60 ℃ 30 seconds → 72 ℃ 1 minute, totally 35 circulations; 72 ℃ 10 minutes, pcr amplification is carried out in 1 circulation, obtains to contain the amplified production of each protein gene of complete open reading frame sequence.Amplified production is through sequence verification, and the sequence that records with embodiment 1 conforms to, and changes amplified production over to host cell with routine techniques subsequently, thereby obtains recombinant protein.

Gene specific primer

Clone's title	Special primer 1 (5 ' → 3 ')	Special primer 2 (5 ' → 3 ')
			PP7027 PP7059 PP7130 PP7298 PP7425 PP7651 PP7664 PP7827 PP7882 PP8038	TGTCTTTGCACCTTGGTCCT CCCTCTTTGCTTGTGAGGAG GCTTCTGAGTAGCGTGGGAG TTATTCTTCGATCTTGCCCG TGTGTGCAGCTAATGGTCGT AGATTCTTCCCAGGCACAAG CAGGCCAGGACTAGTTCCAC ATGGCAACTTCTCCATCACC GATGGTGACAGAGGGGGAC CAGGTGCTTTGTGAGTGGAA	CCTCTACAGGAGGCGTTGAG GGCTCTTACCTCCTGGCTTT TTACCAAGCACGAGTGGACA AGTTGCGACAGCTCAACCTT AATGGGCTGTGATTTGTTCC TTGGAATCCAGGTTGGCTAC CTGGCCTCAAGTGATCTTCC CAGCTGGGCTAGATGACCTC GTCACAAGTGCTCGGTCTGA CTCAGGCCCAGAGCTATCAG

Embodiment 3:cDNA cloned sequence is analyzed

1.PP7027

A: nucleotide sequence (SEQ ID NO:1) length: 2770bp

1 GTTTGAAGAC AAACTTGGAG TTCACTATAT TTAACACTTA GGACCCCTAG TATCTGCCAC

61 TGGGCTGCGG GGGCAGCTGC AGGGACACAC ACCTGTTGGG TGCCTGCTGG TTCCACCCAG

121 GAGCACAGCC AGCAGCCTCA TGCCTCCTGC CCCCTGGCAG TCGGGTGCAC GTGGAGCAGG

181 TGGCCTTGGC CTCGACAGGG TTCCCAGGGT CCCACTGGAA GCCCCACATG GAACTGTGCC

241 TCTGGGACAT TGCTCCAGGG ACCTCGGGTG CGGGCTGGCC CCATCCTGTG GGGAGGTCCT

301 GGGAGGGTCA GTCTGGCCCG CCTGCCTGCT GACTTGGGTG TGGCCTGAGC AGGTAAAGGC

361 GACACAGGAG GAGAACCGGG AGCTGAGGAG CAGGTGTGAG GAGCTCCACG GGAAGAACCT

421 GGAACTGGGG TAAGGAGGCC CCGTCTCCTG TCCTCCCGTC CCCATCCCCC TCGCCATCCT

481 TGTCCCCATC CCCCTCGCCA TCCTTGTCCC CATCCCCCTC GCCATCCCTG TCCCCGTCCC

541 CATCCCCACC TGGCCTGGGA CCGCTGGGCA CCCGAGGCAA TGGCTGTGTG TCTGTTCTCC

601 TCCCACAGGA AGATCATGGA CAGGTTCGAA GAGGTTGTGT ACCAGGCCAT GGGTGAGTGC

661 CCGGGCCACC GAGGCCACGT GCCTCCACGA GGGGCTGCCT ATGCCCCACC CTGGCCCTGC

721 CCTGCACCCT GCCTAGGACC CCACCCTCCT GAGGCCCCTT TTCCTAACAC ACGAGTCCCT

781 TCAACATGGG CCCGGCCGTG GAAGCACTGA GGCGAGTTGC GGGGAAGCTG GTGGTAGTGA

841 GGCTGGTGGC TCCCACGGAG CCAGGGCTTG GCAGGCCCCA CAGTTGTGCA GATGCTGAGC

901 TAGCAGTGGG GCTGTGGTGG GAGCAGAGTC TGTCCCGCCG TGGCCTACCC CACTCCACCC

961 TGCCCTCGCC GTGCGGCTAT GTCTAGCAGC AGCCTCTGTA GGTGTCTGGC AGGACGGGAA

1021 CACCAGGCCT CATCTGGCCT CCCAAAAGCT TGGGCTCCTG GAGGTGCTAC TGTGGGGATC

1081 TGTCTTAGGC TGAGTGTCAG CCGGCGGCAG GTGACCGCCT GGCCCTTGCA GTCCCTCCAG

1141 GACCACCACG AAGCACGACG CACATCCTGG AGCTCGCCAT ACCGGCTCCC AGGCCTCACC

1201 CTAGGCTCTA GGGTGTTGGG CGCCGCCTCT TCAGGGACCT CTGGCCCAGG CTCCAGTTCC

1261 CTGCGGATCT GATGTGGAGG AAACAGCTGT TTCCTGGGCT TTGCATCCGG CCTAGAAGAT

1321 CCCGGGTGGA GGGACCCATC ACCCTCCGAG GCTCACACCC ACTGCCCACC TCTCCTCCTG

1381 GCGCTCGAGT CCCTTGCCTC ATTCCTTGGG CTGTCTCTGG CACCCATCGT TTCGGTTGCC

1441 TCCTCATCCT GAACGTTTGC TTTTCTTTTC TCAAGAGGAA GTTCAGAAGC AGAAGGAACT

1501 TTCCAAAGCT GAAATCCAGA AAGTTCTAAA AGAAAAAGAC CAACTTACCA CAGATCTGAA

1561 CTCCATGGAG AAGTCCTTCT CCGACCTCTT CAAGCGTTTT GAGAAACAGA AAGAGGTGAT

1621 CGAGGGCTAC CGCAAGTATG TCTCCGCCAC CCTGGTGTCC TCACCTCGGA GGCTGATGGA

1681 CTCATGGTCA AGCCAGCGGA CGTAGCAACT GCTGTCTTTG CACCTTGGTC CTTGGCCAAG

1741 CCTCCCCTTG CCACGGGGGC ATGGGATGAC CTGTGAACGA GACAGGGTGC AGGAGTCACA

1801 GCATATGCTG GTTTGCGAGG CAGCTGAGGG CGGCAGGAGG CAGAGTGAGC AGGGAGGCCA

1861 TCTGAGCCGT CCGCTGTTGT GTGACAGACG ACTCGGCTAT GATCAGGCAT CTGTGAGATT

1921 TCAGACAGCG CTGGTGCACC GGGGCCTGGG GCACCTCGGA AAGGTGTCTG GGCTGTCCGA

1981 GCGCTTGGGT CCCAAGGGTT GGGGACCCAG GGCATGCAGT ATCCAAGGCG GGAGGCCCAC

2041 TGAAAGGTGG TCACGGCTGT GCAAGGCCAC CCTGGTGTCC TCCTGGCCAC AGGACTCTGA

2101 GCGCCCCCCA CCTTCTGTGC TGGGCAAGGC CCACATGCTT GCTGGAAGGA GGGATGTCTG

2161 GGCCATCCAT CTGCCCAGAG CAGGCCTGGA AGGTGCCTGC GAGGCCGCCA GAGGGTTCTG

2221 CCCACAGCAG CAATGTTGGA GCGGAGGTGC TCAACGCCTC CTGTAGAGGA GCTGGACCTG

2281 CAGGTGCAGC TGGAAGAGGG GCTGTCACTG TTGGTGCAAG GGGGTTGGGG ACACCAGATG

2341 GGTCCCCTGG GAGTCAGACT AAACTGGAAA AGCGGCCCTT GCAGGGCCTG CTGAGCCACA

2401 CCTCATCTGA GTCCTGAAGT CAGGTGGGTG TCAGTGGCTG GGGCCCAGCT GCCTAACAGA

2461 AGCAAGCCTG AATACTCTAG GGAAGAAGGT ATCTTATGCT TTAAATTGCT GCTGCAGTTT

2521 TAAATTAGTG TCTGGCACAG AATAACCAAG TGTGAAAGGA ACAGGAAACA TGAGTGAAAA

2581 TCAGACCCGT TATTAGAGTG AGGCATGGTG ATGTACACCT GTGGTCCCAG CTACTAGGGA

2641 GGCTGAGGTG GGAGGATCAT TTGAGCCCGG GAGGTTGAAG CTGCAGTGAG CCATGATTGT

2701 ATCACTGCAC CCCCAGCCTG GGCAATAGAC CAAGACCCCC ATCTCTAAAA TTAAAAAAAA

2761 AAAAAAAAAA

B: aminoacid sequence (SEQ ID NO:2) length: 166 amino acid

1 MTCERDRVQE SQHMLVCEAA EGGRRQSEQG GHLSRPLLCD RRLGYDQASV RFQTALVHRG

61 LGHLGKVSGL SERLGPKGWG PRACSIQGGR PTERWSRLCK ATLVSSWPQD SERPPPSVLG

121 KAHMLAGRRD VWAIHLPRAG LEGACEAARG FCPQQQCWSG GAQRLL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:3)

Clone number: PP7027

Start code: 1766ATG stops coding: 2264TAG

Protein molecular weight: 18244.88

1 G TTT GAA GAC AAA CTT GGA GTT CAC TAT ATT TAA CAC TTA GGA CCC 46

47 CTA GTA TCT GCC ACT GGG CTG CGG GGG CAG CTG CAG GGA CAC ACA CCT 94

95 GTT GGG TGC CTG CTG GTT CCA CCC AGG AGC ACA GCC AGC AGC CTC ATG 142

143 CCT CCT GCC CCC TGG CAG TCG GGT GCA CGT GGA GCA GGT GGC CTT GGC 190

191 CTC GAC AGG GTT CCC AGG GTC CCA CTG GAA GCC CCA CAT GGA ACT GTG 238

239 CCT CTG GGA CAT TGC TCC AGG GAC CTC GGG TGC GGG CTG GCC CCA TCC 286

287 TGT GGG GAG GTC CTG GGA GGG TCA GTC TGG CCC GCC TGC CTG CTG ACT 334

335 TGG GTG TGG CCT GAG CAG GTA AAG GCG ACA CAG GAG GAG AAC CGG GAG 382

383 CTG AGG AGC AGG TGT GAG GAG CTC CAC GGG AAG AAC CTG GAA CTG GGG 430

431 TAA GGA GGC CCC GTC TCC TGT CCT CCC GTC CCC ATC CCC CTC GCC ATC 478

479 CTT GTC CCC ATC CCC CTC GCC ATC CTT GTC CCC ATC CCC CTC GCC ATC 526

527 CCT GTC CCC GTC CCC ATC CCC ACC TGG CCT GGG ACC GCT GGG CAC CCG 574

575 AGG CAA TGG CTG TGT GTC TGT TCT CCT CCC ACA GGA AGA TCA TGG ACA 622

623 GGT TCG AAG AGG TTG TGT ACC AGG CCA TGG GTG AGT GCC CGG GCC ACC 670

671 GAG GCC ACG TGC CTC CAC GAG GGG CTG CCT ATG CCC CAC CCT GGC CCT 718

719 GCC CTG CAC CCT GCC TAG GAC CCC ACC CTC CTG AGG CCC CTT TTC CTA 766

767 ACA CAC GAG TCC CTT CAA CAT GGG CCC GGC CGT GGA AGC ACT GAG GCG 814

815 AGT TGC GGG GAA GCT GGT GGT AGT GAG GCT GGT GGC TCC CAC GGA GCC 862

863 AGG GCT TGG CAG GCC CCA CAG TTG TGC AGA TGC TGA GCT AGC AGT GGG 910

911 GCT GTG GTG GGA GCA GAG TCT GTC CCG CCG TGG CCT ACC CCA CTC CAC 958

959 CCT GCC CTC GCC GTG CGG CTA TGT CTA GCA GCA GCC TCT GTA GGT GTC 1006

1007 TGG CAG GAC GGG AAC ACC AGG CCT CAT CTG GCC TCC CAA AAG CTT GGG 1054

1055 CTC CTG GAG GTG CTA CTG TGG GGA TCT GTC TTA GGC TGA GTG TCA GCC 1102

1103 GGC GGC AGG TGA CCG CCT GGC CCT TGC AGT CCC TCC AGG ACC ACC ACG 1150

1151 AAG CAC GAC GCA CAT CCT GGA GCT CGC CAT ACC GGC TCC CAG GCC TCA 1198

1199 CCC TAG GCT CTA GGG TGT TGG GCG CCG CCT CTT CAG GGA CCT CTG GCC 1246

1247 CAG GCT CCA GTT CCC TGC GGA TCT GAT GTG GAG GAA ACA GCT GTT TCC 1294

1295 TGG GCT TTG CAT CCG GCC TAG AAG ATC CCG GGT GGA GGG ACC CAT CAC 1342

1343 CCT CCG AGG CTC ACA CCC ACT GCC CAC CTC TCC TCC TGG CGC TCG AGT 1390

1391 CCC TTG CCT CAT TCC TTG GGC TGT CTC TGG CAC CCA TCG TTT CGG TTG 1438

1439 CCT CCT CAT CCT GAA CGT TTG CTT TTC TTT TCT CAA GAG GAA GTT CAG 1486

1487 AAG CAG AAG GAA CTT TCC AAA GCT GAA ATC CAG AAA GTT CTA AAA GAA 1534

1535 AAA GAC CAA CTT ACC ACA GAT CTG AAC TCC ATG GAG AAG TCC TTC TCC 1582

1583 GAC CTC TTC AAG CGT TTT GAG AAA CAG AAA GAG GTG ATC GAG GGC TAC 1630

1631 CGC AAG TAT GTC TCC GCC ACC CTG GTG TCC TCA CCT CGG AGG CTG ATG 1678

1679 GAC TCA TGG TCA AGC CAG CGG ACG TAG CAA CTG CTG TCT TTG CAC CTT 1726

1727 GGT CCT TGG CCA AGC CTC CCC TTG CCA CGG GGG CAT GGG ATG ACC TGT 1774

1 Met Thr Cys 3

1775 GAA CGA GAC AGG GTG CAG GAG TCA CAG CAT ATG CTG GTT TGC GAG GCA 1822

4 Glu Arg Asp Arg Val Gln Glu Ser Gln His Met Leu Val Cys Glu Ala 19

1823 GCT GAG GGC GGC AGG AGG CAG AGT GAG CAG GGA GGC CAT CTG AGC CGT 1870

20 Ala Glu Gly Gly Arg Arg Gln Ser Glu Gln Gly Gly His Leu Ser Arg 35

1871 CCG CTG TTG TGT GAC AGA CGA CTC GGC TAT GAT CAG GCA TCT GTG AGA 1918

36 Pro Leu Leu Cys Asp Arg Arg Leu Gly Tyr Asp Gln Ala Ser Val Arg 51

1919 TTT CAG ACA GCG CTG GTG CAC CGG GGC CTG GGG CAC CTC GGA AAG GTG 1966

52 Phe Gln Thr Ala Leu Val His Arg Gly Leu Gly His Leu Gly Lys Val 67

1967 TCT GGG CTG TCC GAG CGC TTG GGT CCC AAG GGT TGG GGA CCC AGG GCA 2014

68 Ser Gly Leu Ser Glu Arg Leu Gly Pro Lys Gly Trp Gly Pro Arg Ala 83

2015 TGC AGT ATC CAA GGC GGG AGG CCC ACT GAA AGG TGG TCA CGG CTG TGC 2062

84 Cys Ser Ile Gln Gly Gly Arg Pro Thr Glu Arg Trp Ser Arg Leu Cys 99

2063 AAG GCC ACC CTG GTG TCC TCC TGG CCA CAG GAC TCT GAG CGC CCC CCA 2110

100 Lys Ala Thr Leu Val Ser Ser Trp Pro Gln Asp Ser Glu Arg Pro Pro 115

2111 CCT TCT GTG CTG GGC AAG GCC CAC ATG CTT GCT GGA AGG AGG GAT GTC 2158

116 Pro Ser Val Leu Gly Lys Ala His Met Leu Ala Gly Arg Arg Asp Val 131

2159 TGG GCC ATC CAT CTG CCC AGA GCA GGC CTG GAA GGT GCC TGC GAG GCC 2206

132 Trp Ala Ile His Leu Pro Arg Ala Gly Leu Glu Gly Ala Cys Glu Ala 147

2207 GCC AGA GGG TTC TGC CCA CAG CAG CAA TGT TGG AGC GGA GGT GCT CAA 2254

148 Ala Arg Gly Phe Cys Pro Gln Gln Gln Cys Trp Ser Gly Gly Ala Gln 163

2255 CGC CTC CTG TAG AGG AGC TGG ACC TGC AGG TGC AGC TGG AAG AGG GGC 2302

164 Arg Leu Leu *** 167

2303 TGT CAC TGT TGG TGC AAG GGG GTT GGG GAC ACC AGA TGG GTC CCC TGG 2350

2351 GAG TCA GAC TAA ACT GGA AAA GCG GCC CTT GCA GGG CCT GCT GAG CCA 2398

2399 CAC CTC ATC TGA GTC CTG AAG TCA GGT GGG TGT CAG TGG CTG GGG CCC 2446

2447 AGC TGC CTA ACA GAA GCA AGC CTG AAT ACT CTA GGG AAG AAG GTA TCT 2494

2495 TAT GCT TTA AAT TGC TGC TGC AGT TTT AAA TTA GTG TCT GGC ACA GAA 2542

2543 TAA CCA AGT GTG AAA GGA ACA GGA AAC ATG AGT GAA AAT CAG ACC CGT 2590

2591 TAT TAG AGT GAG GCA TGG TGA TGT ACA CCT GTG GTC CCA GCT ACT AGG 2638

2639 GAG GCT GAG GTG GGA GGA TCA TTT GAG CCC GGG AGG TTG AAG CTG CAG 2686

2687 TGA GCC ATG ATT GTA TCA CTG CAC CCC CAG CCT GGG CAA TAG ACC AAG 2734

2735 ACC CCC ATC TCT AAA ATT AAA AAA AAA AAA AAA AAA 2770

2.PP7059

A: nucleotide sequence (SEQ ID NO:4) length: 2585bp

1 PPCONGCAGC AAGGCTGATG TGGTGGACAG TGAGACTGTG GTACGGGCTC GTGGGTTGCC

61 GTGGCAGTCA TCAGACCAGG ACGTGGCTCG CTTCTTCAAA GGGCTCAACG TGGCCAGGGG

121 TGGTGTAGCA CTCTGCCTCA ACGCCCAGGG CCGCAGAAAT GGCGAGGCCC TCATCCGCTT

181 TGTGGACAGC GAGCAGCGGG ACCTAGCGCT GCAGAGACAC AAGCACCACA TGGGCGTCCG

241 CTATATTGAG GTGTATAAAG CGACAGGGGA GGAGTTTGTA AAGATTGCAG GGGGCACATC

301 ACTAGAGGTG GCTCGTTTCT TGTCACGGGA AGACCAAGTG ATCCTGCGGC TGCGGGGACT

361 GCCCTTCTCG GCTGGCCAAC GGACGTGCTT GGCTTCCTGG GGCCAGAGTG CCCAGTGACT

421 GGGGGTACCG AGGGGCTGCT CTTTGTGCGC CATCCTGATG GCCGGCCGAC TGGTGATGCC

481 TTCGCCCTCT TTGCTTGTGA GGAGCTGGCA CAGGCTGCAC TGCGCAGGCA CAAGGGCATG

541 CTGGGTAAGC GATACATTGA ACTCTTCCGG AGCACTGCAG CCGAAGTGCA GCAGGTCTTG

601 AACCGCTATG CATCCGGCCC ACTCCTTCCT ACACTGACTG CCCCACTGCT GCCCATCCCC

661 TTCCCACTGG CACCTGGGAC TGGGAGGGAC TGTGTACGCC TCCGAGGCCT GCCCTACACG

721 GCCACCATTG AAGACATCCT GAGCTTTCTG GGGGAGGCAG CAGCTGACAT TCGGCCCCAC

781 GGTGTACACA TGGTGCTCAA CCAGCAGGGC CGGCCATCGG GCGATGCCTT CATTCAGATG

841 ACATCAGCAG AGCGAGCCCT AGCTGCTGCT CAGCGTTGCC ATAAGAAGGT GATGAAGGAG

901 CGCTACGTGG AGGTGGTCCC CTGTTCCACA GAGGAGATGA GCCGAGTGCT GATGGGGGGC

961 ACCTTGGGCC GCAGTGGCAT GTCCCCTCCA CCCTGCAAGC TGCCCTGCCT CTCACCACCT

1021 ACCTACACCA CCTTCCAAGC CACCCCAACG CTCATTCCCA CGGAGACGGC AGCTCTATAC

1081 CCCTCTTCAG CACTGCTCCC AGCTGCCAGG GTGCCTGCTG CCCCCACCCC TGTTGCCTAC

1141 TATCCAGGGC CAGCCACTCA ACTCTACCTG AACTACACAG CCTACTACCC AAGCCCCCCA

1201 GTCTCCCCCA CCACTGTGGG CTACCTCACT ACACCCACTG CTGCCCTGGC CTCTGCTCCC

1261 ACCTCAGTGT TGTCCCAGTC AGGAGCCTTG GTCCGCATGC AGGGTGTCCC ATACACGGCT

1321 GGTATGAAGG ATCTGCTCAG CGTCTTCCAG GCCTACCAGC TACCCGCTGA TGACTACACC

1381 AGTCTGATGC CTGTTGGTGA CCCACCTCGC ACTGTGTTAC AAGCCCCCAA GGAATGGGTG

1441 TGTTTGTAGG AGAGAAAGCC AGGAGGTAAG AGCCAGCTGA TATCCTCGGC GAACATGTCT

1501 CTCCTGAGTC CAGAAGACCA GCACCCTCAA CCTGGTAGCT TCTTTCTGGC TTGTCAAAGC

1561 TCTCAGAAGG TACCTAGAGG AGCCCAAGCC CCAGCTCCAT CCTCCACTTA TTCTGCCTGT

1621 TTCCCCCAAA GACAATGGCT GGACCCTGCA TGCAGGGCTG GGGGTGGAAT GGGGCTAACC

1681 AGCTCCTGAT GGCCTGAGCC AGGCATCTTG ACTGGCACCT GGAGAGCCCT TAAGTCTGTC

1741 CTGGCTGTGG CCCATGCCGA CAGATATCGT GGGGCTGACA GGTCCACGGC AGGCTTGCTT

1801 TCTTTTATAA AATGGAAGCT CTGGTACCTT CAATGTATGA CTCCTGGGAG AATCAAGGGT

1861 CCATCTGAGC CTCTGAGTAA AGATCCCAAT GTTCTACCTC TCCCTGTCCC TCTTGTAGGG

1921 GATAGGGAGG CAGAGAGAGC CAGCCCCTAC CCTCAGAGTA TCTGGACCTC AGAGACCATG

1981 TTGTGCCAGG GGTGGTCCCA CCTAAAGATG CTAGCCCCTC TCCAGGTGGG CATAAGGAGT

2041 AACAGATGGC AAAACCACAA ACTATTTTGA TGGACTGTGC TGCAGTATCA CCAGAAGACA

2101 TTAGGGGGCA GTAGGCCCCC ACACAAAACC TTCAGGCTTG AATTTTAAAG GGGAGGACTT

2161 TCTGCCAACT TTTCTTGTAT GCCTTGGGAA AGCCAGTTGC CCTGAACCCA GCAGACACCA

2221 TGGAATGTCC TTTGCACGCA TTAAATGGTA CAGAACTGAA GCCTCGGAAG CAATTTGGAA

2281 CTCGATCTTC TCTTCCTTAA ATGAAAAGTT ATTGACCAAA TGGACTTTTT AAAAGACACA

2341 GGACCCTTAA CTTTGCCCCA AAGTGAGGGG CTCCACACCA ACCCCAGGCG GAGGAACACT

2401 CAGACAGATT AAGGATACTG TTGACCTGTC ACTGTTTATT ATTTCAGCAC TAAAACTGAG

2461 GAGCCTCAAC TGCTGGCTCT TCTTCCCTTT GTATTTGTGT AAGGAGCACT GCACTCCCAT

2521 AAAAGGTTTT AAAATACAAA ATGTACAAGA CCTCTCAAAA AAAAAAAAAA AAAAAAAAAA

2581 AAAAA

B: aminoacid sequence (SEQ ID NO:5) length: 303 amino acid

1 MLGKRYIELF RSTAAEVQQV LNRYASGPLL PTLTAPLLPI PFPLAPGTGR DCVRLRGLPY

61 TATIEDILSF LGEAAADIRP HGVHMVLNQQ GRPSGDAFIQ MTSAERALAA AQRCHKKVMK

121 ERYVEVVPCS TEEMSRVLMG GTLGRSGMSP PPCKLPCLSP PTYTTFQATP TLIPTETAAL

181 YPSSALLPAA RVPAAPTPVA YYPGPATQLY LNYTAYYPSP PVSPTTVGYL TTPTAALASA

241 PTSVLSQSGA LVRMQGVPYT AGMKDLLSVF QAYQLPADDY TSLMPVGDPP RTVLQAPKEW

301 VCL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:6)

Clone number: PP7059

Start code: 533ATG stops coding: 1442TAG

Protein molecular weight: 32452.84

1 G CAG CAA GGC TGA TGT GGT GGA CAG TGA GAC TGT GGT ACG GGC TCG 46

47 TGG GTT GCC GTG GCA GTC ATC AGA CCA GGA CGT GGC TCG CTT CTT CAA 94

95 AGG GCT CAA CGT GGC CAG GGG TGG TGT AGC ACT CTG CCT CAA CGC CCA 142

143 GGG CCG CAG AAA TGG CGA GGC CCT CAT CCG CTT TGT GGA CAG CGA GCA 190

191 GCG GGA CCT AGC GCT GCA GAG ACA CAA GCA CCA CAT GGG CGT CCG CTA 238

239 TAT TGA GGT GTA TAA AGC GAC AGG GGA GGA GTT TGT AAA GAT TGC AGG 286

287 GGG CAC ATC ACT AGA GGT GGC TCG TTT CTT GTC ACG GGA AGA CCA AGT 334

335 GAT CCT GCG GCT GCG GGG ACT GCC CTT CTC GGC TGG CCA ACG GAC GTG 382

383 CTT GGC TTC CTG GGG CCA GAG TGC CCA GTG ACT GGG GGT ACC GAG GGG 430

431 CTG CTC TTT GTG CGC CAT CCT GAT GGC CGG CCG ACT GGT GAT GCC TTC 478

479 GCC CTC TTT GCT TGT GAG GAG CTG GCA CAG GCT GCA CTG CGC AGG CAC 526

527 AAG GGC ATG CTG GGT AAG CGA TAC ATT GAA CTC TTC CGG AGC ACT GCA 574

1 Met Leu Gly Lys Arg Tyr Ile Glu Leu Phe Arg Ser Thr Ala 14

575 GCC GAA GTG CAG CAG GTC TTG AAC CGC TAT GCA TCC GGC CCA CTC CTT 622

15 Ala Glu Val Gln Gln Val Leu Asn Arg Tyr Ala Ser Gly Pro Leu Leu 30

623 CCT ACA CTG ACT GCC CCA CTG CTG CCC ATC CCC TTC CCA CTG GCA CCT 670

31 Pro Thr Leu Thr Ala Pro Leu Leu Pro Ile Pro Phe Pro Leu Ala Pro 46

671 GGG ACT GGG AGG GAC TGT GTA CGC CTC CGA GGC CTG CCC TAC ACG GCC 718

47 Gly Thr Gly Arg Asp Cys Val Arg Leu Arg Gly Leu Pro Tyr Thr Ala 62

719 ACC ATT GAA GAC ATC CTG AGC TTT CTG GGG GAG GCA GCA GCT GAC ATT 766

63 Thr Ile Glu Asp Ile Leu Ser Phe Leu Gly Glu Ala Ala Ala Asp Ile 78

767 CGG CCC CAC GGT GTA CAC ATG GTG CTC AAC CAG CAG GGC CGG CCA TCG 814

79 Arg Pro His Gly Val His Met Val Leu Asn Gln Gln Gly Arg Pro Ser 94

815 GGC GAT GCC TTC ATT CAG ATG ACA TCA GCA GAG CGA GCC CTA GCT GCT 862

95 Gly Asp Ala Phe Ile Gln Met Thr Ser Ala Glu Arg Ala Leu Ala Ala 110

863 GCT CAG CGT TGC CAT AAG AAG GTG ATG AAG GAG CGC TAC GTG GAG GTG 910

111 Ala Gln Arg Cys His Lys Lys Val Met Lys Glu Arg Tyr Val Glu Val 126

911 GTC CCC TGT TCC ACA GAG GAG ATG AGC CGA GTG CTG ATG GGG GGC ACC 958

127 Val Pro Cys Ser Thr Glu Glu Met Ser Arg Val Leu Met Gly Gly Thr 142

959 TTG GGC CGC AGT GGC ATG TCC CCT CCA CCC TGC AAG CTG CCC TGC CTC 1006

143 Leu Gly Arg Ser Gly Met Ser Pro Pro Pro Cys Lys Leu Pro Cys Leu 158

1007 TCA CCA CCT ACC TAC ACC ACC TTC CAA GCC ACC CCA ACG CTC ATT CCC 1054

159 Ser Pro Pro Thr Tyr Thr Thr Phe Gln Ala Thr Pro Thr Leu Ile Pro 174

1055 ACG GAG ACG GCA GCT CTA TAC CCC TCT TCA GCA CTG CTC CCA GCT GCC 1102

175 Thr Glu Thr Ala Ala Leu Tyr Pro Ser Ser Ala Leu Leu Pro Ala Ala 190

1103 AGG GTG CCT GCT GCC CCC ACC CCT GTT GCC TAC TAT CCA GGG CCA GCC 1150

191 Arg Val Pro Ala Ala Pro Thr Pro Val Ala Tyr Tyr Pro Gly Pro Ala 206

1151 ACT CAA CTC TAC CTG AAC TAC ACA GCC TAC TAC CCA AGC CCC CCA GTC 1198

207 Thr Gln Leu Tyr Leu Asn Tyr Thr Ala Tyr Tyr Pro Ser Pro Pro Val 222

1199 TCC CCC ACC ACT GTG GGC TAC CTC ACT ACA CCC ACT GCT GCC CTG GCC 1246

223 Ser Pro Thr Thr Val Gly Tyr Leu Thr Thr Pro Thr Ala Ala Leu Ala 238

1247 TCT GCT CCC ACC TCA GTG TTG TCC CAG TCA GGA GCC TTG GTC CGC ATG 1294

239 Ser Ala Pro Thr Ser Val Leu Ser Gln Ser Gly Ala Leu Val Arg Met 254

1295 CAG GGT GTC CCA TAC ACG GCT GGT ATG AAG GAT CTG CTC AGC GTC TTC 1342

255 Gln Gly Val Pro Tyr Thr Ala Gly Met Lys Asp Leu Leu Ser Val Phe 270

1343 CAG GCC TAC CAG CTA CCC GCT GAT GAC TAC ACC AGT CTG ATG CCT GTT 1390

271 Gln Ala Tyr Gln Leu Pro Ala Asp Asp Tyr Thr Ser Leu Met Pro Val 286

1391 GGT GAC CCA CCT CGC ACT GTG TTA CAA GCC CCC AAG GAA TGG GTG TGT 1438

287 Gly Asp Pro Pro Arg Thr Val Leu Gln Ala Pro Lys Glu Trp Val Cys 302

1439 TTG TAG GAG AGA AAG CCA GGA GGT AAG AGC CAG CTG ATA TCC TCG GCG 1486

303 Leu *** 304

1487 AAC ATG TCT CTC CTG AGT CCA GAA GAC CAG CAC CCT CAA CCT GGT AGC 1534

1535 TTC TTT CTG GCT TGT CAA AGC TCT CAG AAG GTA CCT AGA GGA GCC CAA 1582

1583 GCC CCA GCT CCA TCC TCC ACT TAT TCT GCC TGT TTC CCC CAA AGA CAA 1630

1631 TGG CTG GAC CCT GCA TGC AGG GCT GGG GGT GGA ATG GGG CTA ACC AGC 1678

1679 TCC TGA TGG CCT GAG CCA GGC ATC TTG ACT GGC ACC TGG AGA GCC CTT 1726

1727 AAG TCT GTC CTG GCT GTG GCC CAT GCC GAC AGA TAT CGT GGG GCT GAC 1774

1775 AGG TCC ACG GCA GGC TTG CTT TCT TTT ATA AAA TGG AAG CTC TGG TAC 1822

1823 CTT CAA TGT ATG ACT CCT GGG AGA ATC AAG GGT CCA TCT GAG CCT CTG 1870

1871 AGT AAA GAT CCC AAT GTT CTA CCT CTC CCT GTC CCT CTT GTA GGG GAT 1918

1919 AGG GAG GCA GAG AGA GCC AGC CCC TAC CCT CAG AGT ATC TGG ACC TCA 1966

1967 GAG ACC ATG TTG TGC CAG GGG TGG TCC CAC CTA AAG ATG CTA GCC CCT 2014

2015 CTC CAG GTG GGC ATA AGG AGT AAC AGA TGG CAA AAC CAC AAA CTA TTT 2062

2063 TGA TGG ACT GTG CTG CAG TAT CAC CAG AAG ACA TTA GGG GGC AGT AGG 2110

2111 CCC CCA CAC AAA ACC TTC AGG CTT GAA TTT TAA AGG GGA GGA CTT TCT 2158

2159 GCC AAC TTT TCT TGT ATG CCT TGG GAA AGC CAG TTG CCC TGA ACC CAG 2206

2207 CAG ACA CCA TGG AAT GTC CTT TGC ACG CAT TAA ATG GTA CAG AAC TGA 2254

2255 AGC CTC GGA AGC AAT TTG GAA CTC GAT CTT CTC TTC CTT AAA TGA AAA 2302

2303 GTT ATT GAC CAA ATG GAC TTT TTA AAA GAC ACA GGA CCC TTA ACT TTG 2350

2351 CCC CAA AGT GAG GGG CTC CAC ACC AAC CCC AGG CGG AGG AAC ACT CAG 2398

2399 ACA GAT TAA GGA TAC TGT TGA CCT GTC ACT GTT TAT TAT TTC AGC ACT 2446

2447 AAA ACT GAG GAG CCT CAA CTG CTG GCT CTT CTT CCC TTT GTA TTT GTG 2494

2495 TAA GGA GCA CTG CAC TCC CAT AAA AGG TTT TAA AAT ACA AAA TGT ACA 2542

2543 AGA CCT CTC AAA AAA AAA AAA AAA AAA AAA AAA AAA AA 2580

3.PP7130

A: nucleotide sequence (SEQ ID NO:7) length: 2247bp

1 GTGCATGTGG GGGTTGTGTG TTTAGGGGGG ATCTGTGTCT GCGCTGCGGA GCAAGAGCAA

61 GAGCTAAGGC GATGGCTGAC ATGGCTCTGG GCTTTCCCTA CTCTCAGAAG TACTTGTTGC

121 ATTCCATCTT CGCCAGCGGC CTGGTGAAGT CAGCACTGCT TTTCTCCCCA TTTTGCAGAT

181 GAGATCGTGG GGCTCACCAG CGTCCCCCAT GGCTTCTGAG TAGCGTGGGA GTGGAGTCAG

241 CACCAAGCCA GGCTCCCCGC GCCTGCCTTG CCCTCACCTG CTCCTGCTCT CTGCCAGAGG

301 CAGCATGGTC CGCAGGGCAC CATGGGGCCC GACAGAGTGA CAGCACGAGA ACTGTGCGAG

361 AACGACGACC TGGCCACCAG CCTCGTCCTG GACCCCTACC TCGGTTTCCG CACCCATAAG

421 ATGAACGTCA GCCCTGTGCC CCCCCTGCGG CGACAGCAGC ACCTGCGCTC AGCGCTGGAA

481 ACTTTCCTGA GGCAGCGGGA CCTGGAGGCT GCGTACCGGG CCCTGACGCT GGGAGGCTGG

541 ACGGCCCGCT ACTTCCAGAG CCGGGGCCCG CGGCAGGAGG CTGCCCTCAA GACCCACGTC

601 TATCGCTACC TCCGTGCCTT CCTGCCGGAA AGTGGCTTTA CCATCCTGCC CTGCACGCGC

661 TACTCCATGG AGACCAACGG GGCCAAGATC GTGTCCACTC GTGCTTGGTA AGAGGGCAGG

721 ACTCCCTGCA GGTATCCTTG GAGGAGACAG AGCTCAGAGG GGACAAGAGA GACCCTCTGT

781 TCATGGACTG GCCAACCGGG GAAAAGCGAG GGGCCTGGTC TCCGGGCATC CTAGGAAGGT

841 GGTGGGGCTA ATCCCGGAAG ACCTTTGTGG CTACCATGGT GCCGCTGGAG CAGGAGACCC

901 CGGATGTGAC CCCAGGGTTC CTGGGGCTTC CAGGAAAGAA CTAGGCTTCT GGTCAGGGCC

961 GTGCTGTCCT TACCTCCTTG TGACCTGAGC CCCCACCACA TGTTAAACAC CCCTGAGTGC

1021 AATGAGGAGC CCCTGCCCCT GCCCCTGCCC CTGCCCCTGC GGGGTTCACA GTCTGGTGAG

1081 GAGGTGGGGG GCAGACAAGT CAACATGCAG TCACTGGTCC CAGCTGGTAC ATGCTGCAGG

1141 GGAGCTGTGA GGAATGAGCA AGTGCTCCCA GGGCGAGGCT CACACTGACA GGGGAAGCAC

1201 CCGCCTGAGG GTCTGGTGGG GCGAGTAGGG GGTAGTCCAG GCAGGAGGGA TTTGGGGGCA

1261 GGAGGTGCTA TGAGAGCGAG GGGAGAGAAT GGGGGCTGTA TCTGCTGTGT GCGTGCTGCC

1321 CTGAAGGCTT TCAGTAGAAG GGTCCTGTGG GGCTGTGGGC TGGAGCAGGG AAGCCCACCC

1381 AGGCAGGAGG GGAAGAGGGA GATCTGGAAG ATGGATCGCC AATAGCCAGC ACCAGCGCCC

1441 AGGAGTCCCT CCTTCCTGGG TGCCTCTGTG CCGGAGGCCC GAGTCCCCTG AACACCTGCA

1501 GGAGGCCAGG CATCGCCCAC AGCCCTGCCC CCTGGCCTCT TGGCAGGAAA AAGAATGAGA

1561 AGCTGGAGCT GCTGGTGGGC TGCATTGCAG AGCTGCGGGA GGCAGATGAG GGGCTGCTGA

1621 GGGCCGGTGA GAATGACTTC AGCATCATGT ACTCAACCCG CAAGCGGAGT GCTCAGCTGT

1681 GGCTGGGCCC AGCCGCCTTC ATCAACCATG GTGAGGGTCA GGCAGGTGGA TGGGCAGGAC

1741 GGGATAGAGC CAGGCAGGGC TGGAGGGGTG TAGTGGGAGG GTTCTGCGAC TGAGCTGCCG

1801 AGCTCATCTA CCTCTCTTCT CTCTCCTGCC CCAACTGGCT CCAGACTGCA AACCCAACTG

1861 CAAGGTAAGG CCTTGGGACT CGGGAGGAGA GGGCACGCAG GAAGAAAGGG TGCCTGTGGC

1921 CTGGGGAAAG GGTTTTTGGT CAGTAAAGAG CCAAACACCG GCCGGGCGCG GTGGCTCATG

1981 CCTGTAATCC CAGCACTTTG GGAGGCCGAG GTGGGCAGAT CACGAGGTCA GGAGATGGAG

2041 ACCACGGTGA AACCCCATCT CTACTAAAAA CACAAAAAAT TAGTCGGGCG TGGTGGCGGG

2101 CGCCTGTAGT CTCAGCTACT TGGGAGGCTG AGGCAGGAGA ATGGTGTGAA CCCGGGAGGC

2161 GGAGCTTGCG GTGAGCCGAG ATCGCGCCAC TGCACTCCAG CCTGGGCCAC AGAGCGAGAC

2221 TCTGTCTCAA AAAAAAAAAA AAAAAAA

B: aminoacid sequence (SEQ ID NO:8) length: 129 amino acid

1 MGPDRVTARE LCENDDLATS LVLDPYLGFR THKMNVSPVP PLRRQQHLRS ALETFLRQRD

61 LEAAYRALTL GGWTARYFQS RGPRQEAALK THVYRYLRAF LPESGFTILP CTRYSMETNG

121 AKIVSTRAW

C. Nucleotide and amino acid composite sequence (SEQ ID NO:9)

Clone number: PP7130

Start code: 322ATG stops coding: 709TAA

Protein molecular weight: 14844.21

1 GTG CAT GTG GGG GTT GTG TGT TTA GGG GGG ATC TGT GTC TGC GCT GCG 48

49 GAG CAA GAG CAA GAG CTA AGG CGA TGG CTG ACA TGG CTC TGG GCT TTC 96

97 CCT ACT CTC AGA AGT ACT TGT TGC ATT CCA TCT TCG CCA GCG GCC TGG 144

145 TGA AGT CAG CAC TGC TTT TCT CCC CAT TTT GCA GAT GAG ATC GTG GGG 192

193 CTC ACC AGC GTC CCC CAT GGC TTC TGA GTA GCG TGG GAG TGG AGT CAG 240

241 CAC CAA GCC AGG CTC CCC GCG CCT GCC TTG CCC TCA CCT GCT CCT GCT 288

289 CTC TGC CAG AGG CAG CAT GGT CCG CAG GGC ACC ATG GGG CCC GAC AGA 336

1 Met Gly Pro Asp Arg 5

337 GTG ACA GCA CGA GAA CTG TGC GAG AAC GAC GAC CTG GCC ACC AGC CTC 384

6 Val Thr Ala Arg Glu Leu Cys Glu Asn Asp Asp Leu Ala Thr Ser Leu 21

385 GTC CTG GAC CCC TAC CTC GGT TTC CGC ACC CAT AAG ATG AAC GTC AGC 432

22 Val Leu Asp Pro Tyr Leu Gly Phe Arg Thr His Lys Met Asn Val Ser 37

433 CCT GTG CCC CCC CTG CGG CGA CAG CAG CAC CTG CGC TCA GCG CTG GAA 480

38 Pro Val Pro Pro Leu Arg Arg Gln Gln His Leu Arg Ser Ala Leu Glu 53

481 ACT TTC CTG AGG CAG CGG GAC CTG GAG GCT GCG TAC CGG GCC CTG ACG 528

54 Thr Phe Leu Arg Gln Arg Asp Leu Glu Ala Ala Tyr Arg Ala Leu Thr 69

529 CTG GGA GGC TGG ACG GCC CGC TAC TTC CAG AGC CGG GGC CCG CGG CAG 576

70 Leu Gly Gly Trp Thr Ala Arg Tyr Phe Gln Ser Arg Gly Pro Arg Gln 85

577 GAG GCT GCC CTC AAG ACC CAC GTC TAT CGC TAC CTC CGT GCC TTC CTG 624

86 Glu Ala Ala Leu Lys Thr His Val Tyr Arg Tyr Leu Arg Ala Phe Leu 101

625 CCG GAA AGT GGC TTT ACC ATC CTG CCC TGC ACG CGC TAC TCC ATG GAG 672

102 Pro Glu Ser Gly Phe Thr Ile Leu Pro Cys Thr Arg Tyr Ser Met Glu 117

673 ACC AAC GGG GCC AAG ATC GTG TCC ACT CGT GCC TGG TAA GAG GGC AGG 720

118 Thr Asn Gly Ala Lys Ile Val Ser Thr Arg Ala Trp *** 130

721 ACT CCC TGC AGG TAT CCC TGG AGG AGA CAG AGC TCA GAG GGG ACA AGA 768

769 GAG ACC CCC TGT TCA TGG ACT GGC CAA CCG GGG AAA AGC GAG GGG CCC 816

817 GGT CTC CGG GCA TCC TAG GAA GGT GGT GGG GCC AAT CCC GGA AGA CCC 864

865 TTG TGG CTA CCA TGG TGC CGC TGG AGC AGG AGA CCC CGG ATG TGA CCC 912

913 CAG GGT TCC TGG GGC TTC CAG GAA AGA ACT AGG CTT CTG GTC AGG GCC 960

961 GTG CTG TCC TTA CCT CCT TGT GAC CTG AGC CCC CAC CAC ATG TTA AAC 1008

1009 ACC CCC GAG TGC AAT GAG GAG CCC CCG CCC CTG CCC CTG CCC CTG CCC 1056

1057 CCG CGG GGT TCA CAG TCT GGT GAG GAG GTG GGG GGC AGA CAA GTC AAC 1104

1105 ATG CAG TCA CTG GTC CCA GCT GGT ACA TGC TGC AGG GGA GCC GTG AGG 1152

1153 AAT GAG CAA GTG CCC CCA GGG CGA GGC TCA CAC TGA CAG GGG AAG CAC 1200

1201 CCG CCT GAG GGT CTG GTG GGG CGA GTA GGG GGT AGT CCA GGC AGG AGG 1248

1249 GAT TTG GGG GCA GGA GGT GCT ATG AGA GCG AGG GGA GAG AAT GGG GGC 1296

1297 TGT ATC TGC TGT GTG CGT GCT GCC CCG AAG GCC TTC AGT AGA AGG GTC 1344

1345 CTG TGG GGC TGT GGG CTG GAG CAG GGA AGC CCA CCC AGG CAG GAG GGG 1392

1393 AAG AGG GAG ATC TGG AAG ATG GAT CGC CAA TAG CCA GCA CCA GCG CCC 1440

1441 AGG AGT CCC TCC TTC CTG GGT GCC TCT GTG CCG GAG GCC CGA GTC CCC 1488

1489 TGA ACA CCT GCA GGA GGC CAG GCA TCG CCC ACA GCC CTG CCC CCT GGC 1536

1537 CCC TTG GCA GGA AAA AGA ATG AGA AGC TGG AGC TGC TGG TGG GCT GCA 1584

1585 TTG CAG AGC TGC GGG AGG CAG ATG AGG GGC TGC TGA GGG CCG GTG AGA 1632

1633 ATG ACT TCA GCA TCA TGT ACT CAA CCC GCA AGC GGA GTG CCC AGC TGT 1680

1681 GGC TGG GCC CAG CCG CCC TCA TCA ACC ATG GTG AGG GTC AGG CAG GTG 1728

1729 GAT GGG CAG GAC GGG ATA GAG CCA GGC AGG GCT GGA GGG GTG TAG TGG 1776

1777 GAG GGT TCT GCG ACT GAG CCG CCG AGC TCA TCT ACC TCT CCT CCC TCC 1824

1825 CCT GCC CCA ACT GGC TCC AGA CTG CAA ACC CAA CTG CAA GGT AAG GCC 1872

1873 TTG GGA CCC GGG AGG AGA GGG CAC GCA GGA AGA AAG GGT GCC TGT GGC 1920

1921 CTG GGG AAA GGG TTT TTG GTC AGT AAA GAG CCA AAC ACC GGC CGG GCG 1968

1969 CGG TGG CTC ATG CCC GTA ATC CCA GCA CTT TGG GAG GCC GAG GTG GGC 2016

2017 AGA TCA CGA GGT CAG GAG ATG GAG ACC ACG GTG AAA CCC CAT CTC TAC 2064

2065 TAA AAA CAC AAA AAA TTA GTC GGG CGT GGT GGC GGG CGC CTG TAG TCT 2112

2113 CAG CTA CTT GGG AGG CTG AGG CAG GAG AAT GGT GTG AAC CCG GGA GGC 2160

2161 GGA GCT TGC GGT GAG CCG AGA TCG CGC CAC TGC ACT CCA GCC TGG GCC 2208

2209 ACA GAG CGA GAC TCT GTC TCA AAA AAA AAA AAA AAA AAA 2247

4.PP7298

A: nucleotide sequence (SEQ ID NO:10) length: 2310bp

1 GGCACGGATG GAGCTCACAG TCTAGTGAGA GGTCATGGGC AATAAGTGCA TAAGCTAATT

61 TCCAGATGGT GATAAATGTG GTGGGGGAAA AATACAGGGT ACTGCTATAG AGAATGATTG

121 TAAGTGAGGG TGGGGTTATT CTTGATTGGG TGGTGAGTGT GTGGGAGGAA TATTTTAAGC

181 AGAAAGAATG GCTCAGCCAC AAAATGGAAA TAAGTTTGAA ATGTTGAAGG ACAGAAGGCC

241 AGTGTGGCTG AAGCATTTAG GAAGCTATTA TATAGTCTAA AGGAGTTGGT GGTTTGGTCT

301 AGAATGGTGG TAATTCTGTG TGCGCGCGTG TCTCCCCCGC ACCAACCCTT TTTGCACACT

361 CGAAGCTGAA TATTTTCCTT TTTAGAGAAT TTACCCGCAC CTCCCGCGGG GTTCCCAAGC

421 ACTCTCTCTG CTCCCCTCCC CCCAACCCCC TACCACAGGG CCGCTCCCAG TAGTTTTATT

481 CTTCGATCTT GCCCGGGCCG AGCCTGGCAG GGGCCGGTGG CTCAGCGGGC CTCGCACCCG

541 GCGCTCCGCC GCCGCCGCCG CCCAGCTGCG CCGGGGCGCC CTCCGGAGAT GCTGCCGTGG

601 AAGAAGCACA AGTTCGAGCT GCTGGCCGAG GCGCCGCCGC GGCAGGCGTC CAAGCCCAAG

661 GGCTACGCTG TGAGCCTGCA CTACTCGGCG CTCAGCTCGC TGGCGCGGGC GTGCCCCGAA

721 GGCGCGCTTA GCCGGGTGGG CAGCATGTTC CGCTCCAAGC GCAAGAAGCT GCACATCACT

781 AGCGAGGACC CAACTTACAC CGTGCTCTAC CTGGGCAATG CCACCACCAT CCAGGCGCGC

841 GGCGACGGCT GCACCGACCT TGCTGTGGGC AAGATCTGGA GCAAGAGCGA GGCGGGCCGT

901 CAGGGCACCA AGATGAAGCT GACGGTGAGT GCGCAGGGTA TCCGCATGGT GCACGCCGAG

961 GAGCGCGCGC TGCGCCGCCC GGGCCACCTC TACCTGCTGC ACCGCGTCAC CTACTGCGTG

1021 GCCGACGCGC GGCTGCCCAA GGTCTTCGCC TGGGTGTACC GGCACGAGCT GAAGCACAAG

1081 GCCGTGATGC TGCGCTGCCA CGCCGTGCTG GTGTCCAAGC CCGAAAAGGC GCAGGCCATG

1141 GCCCTGCTGC TCTACCAGAC GTCGGCCAAC GCGCTGGCGG AATTTAAACG CCTCAAGCGG

1201 CGGGACGACG CGCGTCACCA GCAGCAGGAG CTGGTGGGCG CACACACCAT CCCGCTAGTG

1261 CCGCTGCGCA AGCTGCTCCT ACACGGACCC TGCTGCTATA AACCGCCGGT GGAGCGCAGC

1321 CGCAAGCGCG CCCAAGCTTG GCTCCATCAC CGAGGACCTG CTCGGCGAAC AGCTGGAGCA

1381 GGAGCTGCAG GAGGAAGAGG AAGAGGAGCA ACCCGAGGGC TGCCCGGAGG AGGAGGAGAA

1441 CCGTGCGGCA GAGGGAGATC CAGCAGAGGA GGAGGCCGAG GCGCAGCGTG CGCTAGTGGT

1501 CGCCATGCAC TTTGAGTGCG GGGACTTGTT GGATACTCTG GAGAATGGCC GTGGGGAGGC

1561 GCTAGGAGGC GGCGGGGGCT CCCTGGGCCC GGGGGCCGGG CCGCCGCCTC TGCTGCTGGG

1621 CAGCGCCTCC GACATGAAGG TTGAGCTGTC GCAACTTATT AGCGACCTGG GCGAGCTCAG

1681 CTTCGGCAAC GACGTGCGCA CCCTGCAGGC CGACTTGCGG GTGACGCGCC TGCTGTCAGG

1741 CGACAGCACG GGCAGCGAGA GCTCCATCGA GGGCGGGGGC CCTGACGCCA CTTCCGCCAC

1801 CGCCGGGGAC TCGTCCCGCC AGGCCGACGG CGCCAGTGCA GACGAGCCCC ACTCGGGCTG

1861 AGCTCCTCCG CGCGTCGCCG GCGCTCCACC GTGGCTACCC ATCCGTGGTC CCGACAACCT

1921 CCCTGTCCCT TGCCCGCCCC CAGGAAGGGG GAAATGGGGC ATTTGGGGCC CAGACCTACA

1981 CTTGGAGCCC AGGTCCAGCG TTCCCCCGAC CGCTTTCCCC TACCTCCCGG CCCCCGCTCC

2041 CGCCCCAGCA CTTTTGGCTC TGTTGCGCGT GGGGATGCGG GGAGATTTGA GAGGGGAAAA

2101 CCCCGCCAGG AGGGAGAGAG AGGCACCCCT CTGGGATGCG GGTGAGGGAA GGTTGGCTGA

2161 AGTTCCTAGT CTCAGGCCGT AGGTGCCTGG CCAGTTTCCT GTTTGTGGGG CAGCTGGGGC

2221 CTGAGGAGGA GGGGTTCACT TCCTCCTCCC ACCCCCTGGG AGCGGCCCTG CGCTGTCACT

2281 GACATCTCAT TAAAAAAAAA AAAAAAAAAA

B: aminoacid sequence (SEQ ID NO:11) length: 308 amino acid

1 MLPWKKHKFE LLAEAPPRQA SKPKGYAVSL HYSALSSLAR ACPEGALSRV GSMFRSKRKK

61 LHITSEDPTY TVLYLGNATT IQARGDGCTD LAVGKIWSKS EAGRQGTKMK LTVSAQGIRM

121 VHAEERALRR PGHLYLLHRV TYCVADARLP KVFAWVYRHE LKHKAVMLRC HAVLVSKPEK

181 AQAMALLLYQ TSANALAEFK RLKRRDDARH QQQELVGAHT IPLVPLRKLL LHGPCCYKPP

241 VERSRKRAQA WLHHRGPARR TAGAGAAGGR GRGATRGLPG GGGEPCGRGR SSRGGGRGAA

301 CASGRHAL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:12)

Clone number: PP7298

Start code: 589ATG stops coding: 1513TGA

Protein molecular weight: 33697.42

1 GGC ACG GAT GGA GCT CAC AGT CTA GTG AGA GGT CAT GGG CAA TAA GTG 48

49 CAT AAG CTA ATT TCC AGA TGG TGA TAA ATG TGG TGG GGG AAA AAT ACA 96

97 GGG TAC TGC TAT AGA GAA TGA TTG TAA GTG AGG GTG GGG TTA TTC TTG 144

145 ATT GGG TGG TGA GTG TGT GGG AGG AAT ATT TTA AGC AGA AAG AAT GGC 192

193 TCA GCC ACA AAA TGG AAA TAA GTT TGA AAT GTT GAA GGA CAG AAG GCC 240

241 AGT GTG GCT GAA GCA TTT AGG AAG CTA TTA TAT AGT CTA AAG GAG TTG 288

289 GTG GTT TGG TCT AGA ATG GTG GTA ATT CTG TGT GCG CGC GTG TCT CCC 336

337 CCG CAC CAA CCT TTT TTG CAC ACT CGA AGC TGA ATA TTT TCT TTT TTA 384

385 GAG AAT TTA CCC GCA CCT CCT GCG GGG TTC CTA AGC ACT CTC TCT GCT 432

433 CCC CTC CCC CCA ACT CCC TAC CAC AGG GCC GCT CCC AGT AGT TTT ATT 480

481 CTT CGA TCT TGC CCG GGC CGA GCC TGG CAG GGG CCG GTG GCT CAG CGG 528

529 GCC TCG CAC CCG GCG CTC CGC CGC CGC CGC CGC CCA GCT GCG CCG GGG 576

577 CGC CCT CCG GAG ATG CTG CCG TGG AAG AAG CAC AAG TTC GAG CTG CTG 624

1 Met Leu Pro Trp Lys Lys His Lys Phe Glu Leu Leu 12

625 GCC GAG GCG CCG CCG CGG CAG GCG TCC AAG CCC AAG GGC TAC GCT GTG 672

13 Ala Glu Ala Pro Pro Arg Gln Ala Ser Lys Pro Lys Gly Tyr Ala Val 28

673 AGC CTG CAC TAC TCG GCG CTC AGC TCG CTG GCG CGG GCG TGC CCC GAA 720

29 Ser Leu His Tyr Ser Ala Leu Ser Ser Leu Ala Arg Ala Cys Pro Glu 44

721 GGC GCG CTT AGC CGG GTG GGC AGC ATG TTC CGC TCC AAG CGC AAG AAG 768

45 Gly Ala Leu Ser Arg Val Gly Ser Met Phe Arg Ser Lys Arg Lys Lys 60

769 CTG CAC ATC ACT AGC GAG GAC CCA ACT TAC ACC GTG CTC TAC CTG GGC 816

61 Leu His Ile Thr Ser Glu Asp Pro Thr Tyr Thr Val Leu Tyr Leu Gly 76

817 AAT GCC ACC ACC ATC CAG GCG CGC GGC GAC GGC TGC ACC GAC CTT GCT 864

77 Asn Ala Thr Thr Ile Gln Ala Arg Gly Asp Gly CYs Thr Asp Leu Ala 92

865 GTG GGC AAG ATC TGG AGC AAG AGC GAG GCG GGC CGT CAG GGC ACC AAG 912

93 Val Gly Lys Ile Trp Ser Lys Ser Glu Ala Gly Arg Gln Gly Thr Lys 108

913 ATG AAG CTG ACG GTG AGT GCG CAG GGT ATC CGC ATG GTG CAC GCC GAG 960

109 Met Lys Leu Thr Val Ser Ala Gln Gly Ile Arg Met Val His Ala Glu 124

961 GAG CGC GCG CTG CGC CGC CCG GGC CAC CTC TAC CTG CTG CAC CGC GTC 1008

125 Glu Arg Ala Leu Arg Arg Pro Gly His Leu Tyr Leu Leu His Arg Val 140

1009 ACC TAC TGC GTG GCC GAC GCG CGG CTG CCC AAG GTC TTC GCC TGG GTG 1056

141 Thr Tyr Cys Val Ala Asp Ala Arg Leu Pro Lys Val Phe Ala Trp Val 156

1057 TAC CGG CAC GAG CTG AAG CAC AAG GCC GTG ATG CTG CGC TGC CAC GCC 1104

157 Tyr Arg His Glu Leu Lys His Lys Ala Val Met Leu Arg Cys His Ala 172

1105 GTG CTG GTG TCC AAG CCC GAA AAG GCG CAG GCC ATG GCC CTG CTG CTC 1152

173 Val Leu Val Ser Lys Pro Glu Lys Ala Gln Ala Met Ala Leu Leu Leu 188

1153 TAC CAG ACG TCG GCC AAC GCG CTG GCG GAA TTT AAA CGC CTC AAG CGG 1200

189 Tyr Gln Thr Ser Ala Asn Ala Leu Ala Glu Phe Lys Arg Leu Lys Arg 204

1201 CGG GAC GAC GCG CGT CAC CAG CAG CAG GAG CTG GTG GGC GCA CAC ACC 1248

205 Arg Asp Asp Ala Arg His Gln Gln Gln Glu Leu Val Gly Ala His Thr 220

1249 ATC CCG CTA GTG CCG CTG CGC AAG CTG CTC CTA CAC GGA CCC TGC TGC 1296

221 Ile Pro Leu Val Pro Leu Arg Lys Leu Leu Leu His Gly Pro Cys Cys 236

1297 TAT AAA CCG CCG GTG GAG CGC AGC CGC AAG CGC GCC CAA GCT TGG CTC 1344

237 Tyr Lys Pro Pro Val Glu Arg Ser Arg Lys Arg Ala Gln Ala Trp Leu 252

1345 CAT CAC CGA GGA CCT GCT CGG CGA ACA GCT GGA GCA GGA GCT GCA GGA 1392

253 His His Arg Gly Pro Ala Arg Arg Thr Ala Gly Ala Gly Ala Ala Gly 268

1393 GGA AGA GGA AGA GGA GCA ACC CGA GGG CTG CCC GGA GGA GGA GGA GAA 1440

269 Gly Arg Gly Arg Gly Ala Thr Arg Gly Leu Pro Gly Gly Gly Gly Glu 284

1441 CCG TGC GGC AGA GGG AGA TCC AGC AGA GGA GGA GGC CGA GGC GCA GCG 1488

285 Pro Cys Gly Arg Gly Arg Ser Ser Arg Gly Gly Gly Arg Gly Ala Ala 300

1489 TGC GCT AGT GGT CGC CAT GCA CTT TGA GTG CGG GGA CTT GTT GGA TAC 1536

301 Cys Ala Ser Gly Arg His Ala Leu *** 309

1537 TCT GGA GAA TGG CCG TGG GGA GGC GCT AGG AGG CGG CGG GGG CTC CCT 1584

1585 GGG CCC GGG GGC CGG GCC GCC GCC TCT GCT GCT GGG CAG CGC CTC CGA 1632

1633 CAT GAA GGT TGA GCT GTC GCA ACT TAT TAG CGA CCT GGG CGA GCT CAG 1680

1681 CTT CGG CAA CGA CGT GCG CAC CCT GCA GGC CGA CTT GCG GGT GAC GCG 1728

1729 CCT GCT GTC AGG CGA CAG CAC GGG CAG CGA GAG CTC CAT CGA GGG CGG 1776

1777 GGG CCC TGA CGC CAC TTC CGC CAC CGC CGG GGA CTC GTC CCG CCA GGC 1824

1825 CGA CGG CGC CAG TGC AGA CGA GCC CCA CTC GGG CTG AGC TCC TCC GCG 1872

1873 CGT CGC CGG CGC TCC ACC GTG GCT ACC CAT CCG TGG TCC CGA CAA CCT 1920

1921 CCC TGT CCC TTG CCC GCC CCC AGG AAG GGG GAA ATG GGG CAT TTG GGG 1968

1969 CCC AGA CCT ACA CTT GGA GCC CAG GTC CAG CGT TCC CCC GAC CGC TTT 2016

2017 CCC CTA CCT CCC GGC CCC CGC TCC CGC CCC AGC ACT TTT GGC TCT GTT 2064

2065 GCG CGT GGG GAT GCG GGG AGA TTT GAG AGG GGA AAA CCC CGC CAG GAG 2112

2113 GGA GAG AGA GGC ACC CCT CTG GGA TGC GGG TGA GGG AAG GTT GGC TGA 2160

2161 AGT TCC TAG TCT CAG GCC GTA GGT GCC TGG CCA GTT TCC TGT TTG TGG 2208

2209 GGC AGC TGG GGC CTG AGG AGG AGG GGT TCA CTT CCT CCT CCC ACC CCC 2256

2257 TGG GAG CGG CCC TGC GCT GTC ACT GAC ATC TCA TTA AAA AAA AAA AAA 2304

2305 AAA AAA 2310

5.PP7425

A: nucleotide sequence (SEQ ID NO:13) length: 1954bp

1 GTGACGCCCG AGGACCCAGA GGAAACCCAG CCGCTTCTGG GGCCTCCTGG CGGCAGCGCG

61 CCCCGCGGCC GCCGCGTCTT CCTCGCCGCC TTCGCCGCTG CCCTGGGCCC ACTCAGCTTC

121 GGCTTCGCGC TCGGCTACAG CTCCCCGGCC ATCCCTAGCC TGCAGCGCGC CGCGCCCCCG

181 GCCCCGCGCC TGGACGACGC CGCCGCCTCC TGGTTCGGGG CTGTCGTGAC CCTGGGTGCC

241 GCGGCGGGGG GAGTGCTGGG CGGCTGGCTG GTGGACCGCG CCGGGCGCAA GCTGAGCCTC

301 TTGCTGTGCT CCGTGCCCTT CGTGGCCGGC TTTGCCGTCA TCACCGCGGC CCAGGACGTG

361 TGGATGCTGC TGGGGGGCCG CCTCCTCACC GGCCTGGCCT GCGGTGTTGC CTCCCTAGTG

421 GCCCCGGTCT ACATCTCCGA AATCGCCTAC CCAGCAGTCC CGGGGGTTGC TCGGCTCCTG

481 TGTGCAGCTA ATGGTCGTCG TCGGCATCCT CCTGGCCTAC CTGGCAGGCT GGGTGCTGGA

541 GTGGCGCTGG CTGGCTGTGC TGGGCTGCGT GCCCCCCTCC CTCATGCTGC TTCTCATGTG

601 CTTCATGCCC GAGACCCCGC GCTTCCTGCT GACTCAGCAC AGGCGCCAGG AGGCCATGGC

661 CGCCCTGCGG TTCCTGTGGG GCTCCGAGCA GGGCTGGGAA GACCCCCCCA TCGGGGCTGA

721 GCAGAGCTTT CACCTGGCCC TGCTGCGGCA GCCCGGCATC TACAAGCCCT TCATCATCGG

781 CGTCTCCCTG ATGGCCTTCC AGCAGCTGTC GGGGGTCAAC GCCGTCATGT TCTATGCAGA

841 GACCATCTTT GAAGAGGCCA AGTTCAAGGA CAGCAGCCTG GCCTCGGTCG TCGTGGGTGT

901 CATCCAGGTG CTGTTCACAG CTGTGGCGGC TCTCATCATG GACAGAGCAG GGCGGAGGCT

961 GCTCCTGGTC TTGTCAGGTG TGGTCATGGT GTTCAGCACG AGTGCCTTCG GCGCCTACTT

1021 CAAGCTGACC CAGGGTGGCC CTGGCAACTC CTCGCACGTG GCCATCTCGG CGCCTGTCTC

1081 TGCACAGCCT GTTGATGCCA GCGTGGGGCT GGCCTGGCTG GCCGTGGGCA GCATGTGCCT

1141 CTTCATCGCC GGAGGTCCTC AGGCCCTATG GAGCCTTCTG GCTTGCCTCC GCTTTCTGCA

1201 TCTTCAGTGT CCTTTTCACT TTGTTCTGTG TCCCTGAAAC TAAAGGAAAG ACTCTGGAAC

1261 AAATCACAGC CCATTTTGAG GGGCGATGAC AGCCACTCAC TAGGGGATGG AGCAAGCCTG

1321 TGACTCCAAG CTGGGCCCAA GCCCAGAGCC CCTGCCTGCC CCAGGGGAGC CAGAATCCAG

1381 CCCCTTGCAG CCTTGGTCTG CAGGGTCCCT CCTTCCTGTC ATGCTCCCTC CAGCCCATGA

1441 CCCGGGGCTA GGAGGCTCAC TGCCTCCTGT TCCAGCTCCT GCTGCTGCTC TGAGGACTCA

1501 GGAACACCTT CGAGCTTTGC AGACCTGCGG TCAGCCCTCC ATGCGCAAGA CTAAAGCAGC

1561 GGAAGAGGAG GTGGGCCTCT AGGATCTTTG TCTTCTGGCT GGAGGTGCTT TTGGAGGTTG

1621 GGTGCTGGGC ATTCAGTCGC TCCTCTCACG CGGCTGCCTT ATCGGGAAGG AAATTTGTTT

1681 GCCAAATAAA GACTGACACA GAAAATCAGG TCAGTGTCTC TGGGCTTTGT GCAAGCTCAG

1741 TTTGAAAAGG GTTTATTCCC ATCACTGCCC AGGACACCCT GTGGCTTTAC TTGCTCATGG

1801 TCAGCCAAGC TTACCCTTCA CACTGAGAAG TCATTTCTGG CTACTTCCTT GGGCTCAGTT

1861 CCCTGGGTCA TCAGCCATCA AATCTTGTTG AGTTTAAAAA ATAAACAGCA AAAAAAAACA

1921 AACAAAACAA AAAAAAAAAA AAAAAAAAAA AAAA

B: aminoacid sequence (SEQ ID NO:14) length: 248 amino acid

1 MVVVGILLAY LAGWVLEWRW LAVLGCVPPS LMLLLMCFMP ETPRFLLTQH RRQEAMAALR

61 FLWGSEQGWE DPPIGAEQSF HLALLRQPGI YKPFIIGVSL MAFQQLSGVN AVMFYAETIF

121 EEAKFKDSSL ASVVVGVIQV LFTAVAALIM DRAGRRLLLV LSGVVMVFST SAFGAYFKLT

181 QGGPGNSSHV AISAPVSAQP VDASVGLAWL AVGSMCLFIA GGPQALWSLL ACLRFLHLQC

241 PFHFVLCP

C. Nucleotide and amino acid composite sequence (SEQ ID NO:15)

Clone number: PP7425

Start code: 491ATG stops coding: 1235TGA

Protein molecular weight: 27015.64

1 G TGA CGC CCG AGG ACC CAG AGG AAA CCC AGC CGC TTC TGG GGC CTC 46

47 CTG GCG GCA GCG CGC CCC GCG GCC GCC GCG TCT TCC TCG CCG CCT TCG 94

95 CCG CTG CCC TGG GCC CAC TCA GCT TCG GCT TCG CGC TCG GCT ACA GCT 142

143 CCC CGG CCA TCC CTA GCC TGC AGC GCG CCG CGC CCC CGG CCC CGC GCC 190

191 TGG ACG ACG CCG CCG CCT CCT GGT TCG GGG CTG TCG TGA CCC TGG GTG 238

239 CCG CGG CGG GGG GAG TGC TGG GCG GCT GGC TGG TGG ACC GCG CCG GGC 286

287 GCA AGC TGA GCC TCT TGC TGT GCT CCG TGC CCT TCG TGG CCG GCT TTG 334

335 CCG TCA TCA CCG CGG CCC AGG ACG TGT GGA TGC TGC TGG GGG GCC GCC 382

383 TCC TCA CCG GCC TGG CCT GCG GTG TTG CCT CCC TAG TGG CCC CGG TCT 430

431 ACA TCT CCG AAA TCG CCT ACC CAG CAG TCC CGG GGG TTG CTC GGC TCC 478

479 TGT GTG CAG CTA ATG GTC GTC GTC GGC ATC CTC CTG GCC TAC CTG GCA 526

1 Met Val Val Val Gly Ile Leu Leu Ala Tyr Leu Ala 12

527 GGC TGG GTG CTG GAG TGG CGC TGG CTG GCT GTG CTG GGC TGC GTG CCC 574

13 Gly Trp Val Leu Glu Trp Arg Trp Leu Ala Val Leu Gly Cys Val Pro 28

575 CCC TCC CTC ATG CTG CTT CTC ATG TGC TTC ATG CCC GAG ACC CCG CGC 622

29 Pro Ser Leu Met Leu Leu Leu Met Cys Phe Met Pro Glu Thr Pro Arg 44

623 TTC CTG CTG ACT CAG CAC AGG CGC CAG GAG GCC ATG GCC GCC CTG CGG 670

45 Phe Leu Leu Thr Gln His Arg Arg Gln Glu Ala Met Ala Ala Leu Arg 60

671 TTC CTG TGG GGC TCC GAG CAG GGC TGG GAA GAC CCC CCC ATC GGG GCT 718

61 Phe Leu Trp Gly Ser Glu Gln Gly Trp Glu Asp Pro Pro Ile Gly Ala 76

719 GAG CAG AGC TTT CAC CTG GCC CTG CTG CGG CAG CCC GGC ATC TAC AAG 766

77 Glu Gln Ser Phe His Leu Ala Leu Leu Arg Gln Pro Gly Ile Tyr Lys 92

767 CCC TTC ATC ATC GGC GTC TCC CTG ATG GCC TTC CAG CAG CTG TCG GGG 814

93 Pro Phe Ile Ile Gly Val Ser Leu Met Ala Phe Gln Gln Leu Ser Gly 108

815 GTC AAC GCC GTC ATG TTC TAT GCA GAG ACC ATC TTT GAA GAG GCC AAG 862

109 Val Asn Ala Val Met Phe Tyr Ala Glu Thr Ile Phe Glu Glu Ala Lys 124

863 TTC AAG GAC AGC AGC CTG GCC TCG GTC GTC GTG GGT GTC ATC CAG GTG 910

125 Phe Lys Asp Ser Ser Leu Ala Ser Val Val Val Gly Val Ile Gln Val 140

911 CTG TTC ACA GCT GTG GCG GCT CTC ATC ATG GAC AGA GCA GGG CGG AGG 958

141 Leu Phe Thr Ala Val Ala Ala Leu Ile Met Asp Arg Ala Gly Arg Arg 156

959 CTG CTC CTG GTC TTG TCA GGT GTG GTC ATG GTG TTC AGC ACG AGT GCC 1006

157 Leu Leu Leu Val Leu Ser Gly Val Val Met Val Phe Ser Thr Ser Ala 172

1007 TTC GGC GCC TAC TTC AAG CTG ACC CAG GGT GGC CCT GGC AAC TCC TCG 1054

173 Phe Gly Ala Tyr Phe Lys Leu Thr Gln Gly Gly Pro Gly Asn Ser Ser 188

1055 CAC GTG GCC ATC TCG GCG CCT GTC TCT GCA CAG CCT GTT GAT GCC AGC 1102

189 His Val Ala Ile Ser Ala Pro Val Ser Ala Gln Pro Val Asp Ala Ser 204

1103 GTG GGG CTG GCC TGG CTG GCC GTG GGC AGC ATG TGC CTC TTC ATC GCC 1150

205 Val Gly Leu Ala Trp Leu Ala Val Gly Ser Met Cys Leu Phe Ile Ala 220

1151 GGA GGT CCT CAG GCC CTA TGG AGC CTT CTG GCT TGC CTC CGC TTT CTG 1198

221 Gly Gly Pro Gln Ala Leu Trp Ser Leu Leu Ala Cys Leu Arg Phe Leu 236

1199 CAT CTT CAG TGT CCT TTT CAC TTT GTT CTG TGT CCC TGA AAC TAA AGG 1246

237 His Leu Gln Cys Pro Phe His Phe Val Leu Cys Pro *** 249

1247 AAA GAC TCT GGA ACA AAT CAC AGC CCA TTT TGA GGG GCG ATG ACA GCC 1294

1295 ACT CAC TAG GGG ATG GAG CAA GCC TGT GAC TCC AAG CTG GGC CCA AGC 1342

1343 CCA GAG CCC CTG CCT GCC CCA GGG GAG CCA GAA TCC AGC CCC TTG CAG 1390

1391 CCT TGG TCT GCA GGG TCC CTC CTT CCT GTC ATG CTC CCT CCA GCC CAT 1438

1439 GAC CCG GGG CTA GGA GGC TCA CTG CCT CCT GTT CCA GCT CCT GCT GCT 1486

1487 GCT CTG AGG ACT CAG GAA CAC CTT CGA GCT TTG CAG ACC TGC GGT CAG 1534

1535 CCC TCC ATG CGC AAG ACT AAA GCA GCG GAA GAG GAG GTG GGC CTC TAG 1582

1583 GAT CTT TGT CTT CTG GCT GGA GGT GCT TTT GGA GGT TGG GTG CTG GGC 1630

1631 ATT CAG TCG CTC CTC TCA CGC GGC TGC CTT ATC GGG AAG GAA ATT TGT 1678

1679 TTG CCA AAT AAA GAC TGA CAC AGA AAA TCA GGT CAG TGT CTC TGG GCT 1726

1727 TTG TGC AAG CTC AGT TTG AAA AGG GTT TAT TCC CAT CAC TGC CCA GGA 1774

1775 CAC CCT GTG GCT TTA CTT GCT CAT GGT CAG CCA AGC TTA CCC TTC ACA 1822

1823 CTG AGA AGT CAT TTC TGG CTA CTT CCT TGG GCT CAG TTC CCT GGG TCA 1870

1871 TCA GCC ATC AAA TCT TGT TGA GTT TAA AAA ATA AAC AGC AAA AAA AAA 1918

1919 CAA ACA AAA CAA AAA AAA AAA AAA AAA AAA AAA AAA 1954

6.PP7651

A: nucleotide sequence (SEQ ID NO:16) length: 2463bp

1 GTTTGTCTCA CACAAGTGCA TCCCTGTCCA TTTCTAAGTG CGCCCTTGTC CTTTGGGGAG

61 TGTGGCCTGT GAAACATGGT GCATGCCTGC AGTTATGTGT GTGTTTGAAA ACACAAGATC

121 CTGCACGGGG AAGTGGTTGA GTGTGTGTTT GTGCATATGC GTGGGTGTGT CGCTGCCTTG

181 TAGGCAAGCA TGTTCACCTG TGATCGGTCT TCCTGAGTAC ATGCAGGCAT GGAGGCAAAC

241 ATGCACCTCT GCAGAAGTGT TCACATGTGA TGAAGTCCAT CCACATGTTT GCAGGGGTTT

301 GAGTGTGTCA TCCCCCAGCT AGAAGCTTGC GTTTGTGCAG TGGGACATGC ATCAGTCCTG

361 CACATATAGC CTTGGGGCTC ATTACACCAG CCAGCCTCCT CTCCCCACTT CCCCAGAAGG

421 GGAGGCCTTG CCATGCCCTG GGGGAGGAGA CGGTGGAGTC CAGAGGTTGA CCTGAAAGAG

481 TGAGATTCTT CCCAGGCACA AGCACACAGA TGGGCTCAGC CACAGTGCTC CTGGCAGGTT

541 TACAGCTGGA AAACAACACA AAAAATTTTT ATCTTGTGTT GAAAATAACT ACTACCCTGA

601 CCGTGACCCC AGGGCTTCCT CTGAGTAAGG AGAGACCTCC TAGACTCCTT AGCATCCAGA

661 TTCCCTCGCT TCCCAGAGGG CAACCCAAAA GCACAGAGCC CCAAGGCCCA GCTCCTGCCC

721 CTAAGCTCTC CTGCCCATCT CTCTCTCCCA CCCCCACTTG GTTCCACGCA TTCTTCAGCC

781 ATGACATCCT CACTCCAGGA GCTCAGCAGC CAGGGCCATG CCCTGCCCTG CCTTGCACTT

841 GCTCTGCCCT GGTTCTACAC TGGCCCTGGA CCCGCAGGCC AGCACAGTTC TGTGGCCTCT

901 GCACCAGGGT TTCACTCAAG GAGGAGTGGG GGCAGAGAGT GTGGGTGAGC CAGCGTTCCC

961 TGAGGAGGTC TAGAGCTGAC TTTGAGCTTA CGGGTTGTGT TGGGATAATA TTAAAGTGGC

1021 TGGTGGGTGC GTACCGTGTT GCATGCTCTG TGCTGGGGGT TCGTGTATAT GTCTTATTTC

1081 ATGCAGTAAT CCTAGGAGAC AGATTCTGTT ATGTAGGAGA ACACTGAGGC TTAGAAGAGT

1141 TTACATGACT TGTCAGCTAA TAGTAGCCAA CCTGGATTCC AAGACAGGTC TGTCTGACTC

1201 CAAAGACCTT GCCCTTTGCT CTATGTCCAA AGGTGAGTCT AAATGTCCAG CCACACCTGT

1261 ATGCGGTGAT GCCTGTGGGT TTGGGTGTGG GAGCCTGCAG GTACAATGCC TGTGAAAGGT

1321 ATAATATGTG TGTACGGGCA CAGTAGCTTA TGCCTGTAAT CCCAGCACTT TGGGAGGCCA

1381 AGGCAGGAGG ATCACCTGTG GTCAGGAGTT CAAGAACAGC CTGATCAACA AGGTGAAACC

1441 TCGTCTCTAC TAAAAAAAAA AATACAAAAA TTAGCTGGGC GAGGCTGAGA CAGGAGAATT

1501 GCTTGAACCC AGGAGGCAGA GGTTGCAGTG AGCTGAGATT GCACCACTGC ACTCCAGCCT

1561 GGGTGACAGA GTGAGACTCC ATTTCAAAAA AAAAAGAAAG AAAGGTATAA CACAAGCCTA

1621 AGTGTGGAGG CATTCGTGTG GCAGATGCAC ATCTACGTGA ACTTTGGTGA GTATGAACCC

1681 ACTGCTTCTT CCTTGGAGTG TACCTCCCAT CCCATGTCCT TGTTAAGGCC ACTCTGCATG

1741 TCACCTGGGA AGCATCTTCT GTTGCCGTCC CATCAGTTGC TGAGCCAAGG CCACCTGCCG

1801 AGGATGGCGA TTCAAGTAAG AGTAGCTTTC TCATGGGTTG GAAGAGATTT GGGGTCACTT

1861 ACTGGCTGGT GACCTTGAGT GAGTTATCGC CCTTCATAGG CTCAAGTGTT CTGATGTCTA

1921 AAGTCAGGGA GGTGGGCTGG AACCTAAACC TAGCCACTTA GGTTATCTCT CTCTGAGAGT

1981 TTCTAATGCT CTGCAAGAGC ATGGTGTGGA GTGTGGCTTA CTGGGCATGT TGTGGGCAGG

2041 CCAGGATTAA ATTAATTAAT GGGAAAGCAC TTTGCCAATT GGAAAGCACC ACAAAAATTT

2101 CAACATTTAC ATAAGGTGTC ATTATCACGA CTATTATTTG CTTAATGGGT CCAGAGCTTG

2161 CAGCTGGTTT GTGTATGTTG GAGCTTGTGC ATGTGTGTTT TTTAAAAACC GTGTGTGACT

2221 GTGTGTGTAT TTTGTTGTGG ATGTGTCCGT CTGAGTATCT ATTTTGATAT ATGTATTTAC

2281 AGTAGGGGTT CTAGAGAGTG CAAGTGGGTG CTGCACTGGG AATGGGGAAG GCCTGAGTTA

2341 TACGTCCAGT TTTCCAGTGA CTAGCAATTA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

2401 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

2461 AAA

B: aminoacid sequence (SEQ ID NO:17) length: 205 amino acid

1 MGSATVLLAG LQLENNTKNF YLVLKITTTL TVTPGLPLSK ERPPRLLSIQ IPSLPRGQPK

61 STEPQGPAPA PKLSCPSLSP TPTWFHAFFS HDILTPGAQQ PGPCPALPCT CSALVLHWPW

121 TRRPAQFCGL CTRVSLKEEW GQRVWVSQRS LRRSRADFEL TGCVGIILKW LVGAYRVACS

181 VLGVRVYVLF HAVILGDRFC YVGEH

C. Nucleotide and amino acid composite sequence (SEQ ID NO:18)

Clone number: PP7651

Start code: 510ATG stops coding: 1125TGA

Protein molecular weight: 22613.30

1 GT TTG TCT CAC ACA AGT GCA TCC CTG TCC ATT TCT AAG TGC GCC CTT 47

48 GTC CTT TGG GGA GTG TGG CCT GTG AAA CAT GGT GCA TGC CTG CAG TTA 95

96 TGT GTG TGT TTG AAA ACA CAA GAT CCT GCA CGG GGA AGT GGT TGA GTG 143

144 TGT GTT TGT GCA TAT GCG TGG GTG TGT CGC TGC CTT GTA GGC AAG CAT 191

192 GTT CAC CTG TGA TCG GTC TTC CTG AGT ACA TGC AGG CAT GGA GGC AAA 239

240 CAT GCA CCT CTG CAG AAG TGT TCA CAT GTG ATG AAG TCC ATC CAC ATG 287

288 TTT GCA GGG GTT TGA GTG TGT CAT CCC CCA GCT AGA AGC TTG CGT TTG 335

336 TGC AGT GGG ACA TGC ATC AGT CCT GCA CAT ATA GCC TTG GGG CTC ATT 383

384 ACA CCA GCC AGC CTC CTC TCC CCA CTT CCC CAG AAG GGG AGG CCT TGC 431

432 CAT GCC CTG GGG GAG GAG ACG GTG GAG TCC AGA GGT TGA CCT GAA AGA 479

480 GTG AGA TTC TTC CCA GGC ACA AGC ACA CAG ATG GGC TCA GCC ACA GTG 527

1 Met Gly Ser Ala Thr Val 6

528 CTC CTG GCA GGT TTA CAG CTG GAA AAC AAC ACA AAA AAT TTT TAT CTT 575

7 Leu Leu Ala Gly Leu Gln Leu Glu Asn Asn Thr Lys Asn Phe Tyr Leu 22

576 GTG TTG AAA ATA ACT ACT ACC CTG ACC GTG ACC CCA GGG CTT CCT CTG 623

23 Val Leu Lys Ile Thr Thr Thr Leu Thr Val Thr Pro Gly Leu Pro Leu 38

624 AGT AAG GAG AGA CCT CCT AGA CTC CTT AGC ATC CAG ATT CCC TCG CTT 671

39 Ser Lys Glu Arg Pro Pro Arg Leu Leu Ser Ile Gln Ile Pro Ser Leu 54

672 CCC AGA GGG CAA CCC AAA AGC ACA GAG CCC CAA GGC CCA GCT CCT GCC 719

55 Pro Arg Gly Gln Pro Lys Ser Thr Glu Pro Gln Gly Pro Ala Pro Ala 70

720 CCT AAG CTC TCC TGC CCA TCT CTC TCT CCC ACC CCC ACT TGG TTC CAC 767

71 Pro Lys Leu Ser Cys Pro Ser Leu Ser Pro Thr Pro Thr Trp Phe His 86

768 GCA TTC TTC AGC CAT GAC ATC CTC ACT CCA GGA GCT CAG CAG CCA GGG 815

87 Ala Phe Phe Ser His Asp Ile Leu Thr Pro Gly Ala Gln Gln Pro Gly 102

816 CCA TGC CCT GCC CTG CCT TGC ACT TGC TCT GCC CTG GTT CTA CAC TGG 863

103 Pro Cys Pro Ala Leu Pro Cys Thr Cys Ser Ala Leu Val Leu His Trp 118

864 CCC TGG ACC CGC AGG CCA GCA CAG TTC TGT GGC CTC TGC ACC AGG GTT 911

119 Pro Trp Thr Arg Arg Pro Ala Gln Phe Cys Gly Leu Cys Thr Arg Val 134

912 TCA CTC AAG GAG GAG TGG GGG CAG AGA GTG TGG GTG AGC CAG CGT TCC 959

135 Ser Leu Lys Glu Glu Trp Gly Gln Arg Val Trp Val Ser Gln Arg Ser 150

960 CTG AGG AGG TCT AGA GCT GAC TTT GAG CTT ACG GGT TGT GTT GGG ATA 1007

151 Leu Arg Arg Ser Arg Ala Asp Phe Glu Leu Thr Gly Cys Val Gly Ile 166

1008 ATA TTA AAG TGG CTG GTG GGT GCG TAC CGT GTT GCA TGC TCT GTG CTG 1055

167 Ile Leu Lys Trp Leu Val Gly Ala Tyr Arg Val Ala Cys Ser Val Leu 182

1056 GGG GTT CGT GTA TAT GTC TTA TTT CAT GCA GTA ATC CTA GGA GAC AGA 1103

183 Gly Val Arg Val Tyr Val Leu Phe His Ala Val Ile Leu Gly Asp Arg 198

1104 TTC TGT TAT GTA GGA GAA CAC TGA GGC TTA GAA GAG TTT ACA TGA CTT 1151

199 Phe Cys Tyr Val Gly Glu His *** 206

1152 GTC AGC TAA TAG TAG CCA ACC TGG ATT CCA AGA CAG GTC TGT CTG ACT 1199

1200 CCA AAG ACC TTG CCC TTT GCT CTA TGT CCA AAG GTG AGT CTA AAT GTC 1247

1248 CAG CCA CAC CTG TAT GCG GTG ATG CCT GTG GGT TTG GGT GTG GGA GCC 1295

1296 TGC AGG TAC AAT GCC TGT GAA AGG TAT AAT ATG TGT GTA CGG GCA CAG 1343

1344 TAG CTT ATG CCT GTA ATC CCA GCA CTT TGG GAG GCC AAG GCA GGA GGA 1391

1392 TCA CCT GTG GTC AGG AGT TCA AGA ACA GCC TGA TCA ACA AGG TGA AAC 1439

1440 CTC GTC TCT ACT AAA AAA AAA AAT ACA AAA ATT AGC TGG GCG AGG CTG 1487

1488 AGA CAG GAG AAT TGC TTG AAC CCA GGA GGC AGA GGT TGC AGT GAG CTG 1535

1536 AGA TTG CAC CAC TGC ACT CCA GCC TGG GTG ACA GAG TGA GAC TCC ATT 1583

1584 TCA AAA AAA AAA GAA AGA AAG GTA TAA CAC AAG CCT AAG TGT GGA GGC 1631

1632 ATT CGT GTG GCA GAT GCA CAT CTA CGT GAA CTT TGG TGA GTA TGA ACC 1679

1680 CAC TGC TTC TTC CTT GGA GTG TAC CTC CCA TCC CAT GTC CTT GTT AAG 1727

1728 GCC ACT CTG CAT GTC ACC TGG GAA GCA TCT TCT GTT GCC GTC CCA TCA 1775

1776 GTT GCT GAG CCA AGG CCA CCT GCC GAG GAT GGC GAT TCA AGT AAG AGT 1823

1824 AGC TTT CTC ATG GGT TGG AAG AGA TTT GGG GTC ACT TAC TGG CTG GTG 1871

1872 ACC TTG AGT GAG TTA TCG CCC TTC ATA GGC TCA AGT GTT CTG ATG TCT 1919

1920 AAA GTC AGG GAG GTG GGC TGG AAC CTA AAC CTA GCC ACT TAG GTT ATC 1967

1968 TCT CTC TGA GAG TTT CTA ATG CTC TGC AAG AGC ATG GTG TGG AGT GTG 2015

2016 GCT TAC TGG GCA TGT TGT GGG CAG GCC AGG ATT AAA TTA ATT AAT GGG 2063

2064 AAA GCA CTT TGC CAA TTG GAA AGC ACC ACA AAA ATT TCA ACA TTT ACA 2111

2112 TAA GGT GTC ATT ATC ACG ACT ATT ATT TGC TTA ATG GGT CCA GAG CTT 2159

2160 GCA GCT GGT TTG TGT ATG TTG GAG CTT GTG CAT GTG TGT TTT TTA AAA 2207

2208 ACC GTG TGT GAC TGT GTG TGT ATT TTG TTG TGG ATG TGT CCG TCT GAG 2255

2256 TAT CTA TTT TGA TAT ATG TAT TTA CAG TAG GGG TTC TAG AGA GTG CAA 2303

2304 GTG GGT GCT GCA CTG GGA ATG GGG AAG GCC TGA GTT ATA CGT CCA GTT 2351

2352 TTC CAG TGA CTA GCA ATT AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 2399

2400 AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 2447

2448 AAA AAA AAA AAA AAA A 2463

7.PP7664

A: nucleotide sequence (SEQ ID NO:19) length: 2078bp

1 GGCAGGCCAG GACTAGTTCC ACGGCCCTGA GCATGCGTTA GCCCCTTCTT GCCTCCATGC

61 ATCAGTTTAC CTCGGAGTGA GCTGCGGGAG ACGTCTCCCT GCCTGGCCGG GGCGGCTCTG

121 TCGTAGCGGA GGGCAGCGGT GGTGCAGATC CGGAGCCGGA GCCGGAGCCG CGCCGCGCCG

181 CACCATGGCG CCCACCCTGG CCACTGCCCA TCGGCGCCGC TGGTGGATGG CCTGCACGCC

241 CGTGCTGGAG AACCTCCTCT TCTCGGCAGT CCTCCTGGGC TGGGGCTCGC TGCTCATCAT

301 GCTCAAGTCA GAGGGCTTTT ACTCCTACCT GTGTACCGAG CCAGAGAATG TCACCAATGG

361 CACAGTGGGC GGCACAGCAG AGCCGGGGCA CGAGGAGGTG AGCTGGATGA ACGGCTGGCT

421 CAGCTGCCAG GCCCAGGACG AGATGCTAAA TTTGGCCTTC ACTGTGGGCT CCTTTCTGCT

481 CAGTGCCATC ACCCTGCCCC TGGGTATCGT CATGGACAAG TATGGCCCGA GGAAGCTCAG

541 GCTGCTGGGC AGCGCCTGCT TCGCGGTTTC CTGCTTGCTG ATTGCGTACG GAGCAAGTAA

601 ACCAAACGCT CTCTCCGTGC TCATCTTCAT CGCCCTGGCT CTGAATGGCT TTGGTGGGAT

661 GTGTATGACC TTCACCTCAT TAACACTGCC CAACATGTTC GGCGACCTTC GGTCCACGTT

721 TATTGCCTTG ATGATTGGGT CCTACGCCTC CTCGGCAGTC ACCTTTCCAG GAATCAAGCT

781 CATCTATGAT GCTGGTGTCT CCTTCATCGT CGTCCTCGTG GTCTGGGCCG GCTGCTCCGG

841 GCTGGTTTTC CTCAACTGCT TCTTTAACTG GCCCCTTGAG CCCTTCCCGG GGCCGGAGGA

901 CATGGACTAC TCGGTGAAGA TCAAGTTCAG CTGGCTGGGC TTTGACCACA AGATCACAGG

961 GAAGCAGTTC TACAAGCAGG TGACCACGGT GGGCCGGCGC CTGAGTGTGG GCAGCTCCAT

1021 GAGGAGTGCC AAGGAGCAGG TGGCGCTGCA GGAGGGCCAC AAGCTGTGCC TGTCCACCGT

1081 CGACCTGGAG GTGAAGTGCC AGCCGGATGC CGCAGTGGCC CCCTCCTTCA TGCACAGCGT

1141 GTTCAGCCCC ATCCTGCTGC TCAGCCTGGT CACCATGTGC GTCACGCAGC TGCGGCTCAT

1201 CTTCTACATG GGGGCTATGA ACAACATCCT CAAGTTCCTG GTCAGCGGCG ACCAGAAGAC

1261 AGTTGGCCTC TACACCTCCA TCTTCGGCGT GCTCCAGCTG CTGTGCCTGC TGACGGCCCC

1321 CGTCATTGGC TACATCATGG ACTGGAGGCT GAAGGAGTGT GAAGACGCCT CCGAGGAGCC

1381 CGAGGAGAAA GACGCCAACC AGTGCGTAGG CAGGGCCGGT GCCCCGGCTC CCAGCCCGCA

1441 GCCCCTGCAG AAAGACCCCA GAGCTGCATG TCAGGCACAG GGTGGGTGGG ACAGAGGGAG

1501 AGAGCAATGC ACTCCAGCTC CTCCCGGAGC CCTTAGAGAG GCTCACTCAT TCAGCTCAGC

1561 ATGCGTTTCA ACTGCTCCCC TCTTTATGGA AATTGTTTGG AATGCAATGG AAATGCTAGA

1621 GTTTGAGGCC AGGTGCGGTG ACTCATGCCT GTAATCCCAA GCACTTTGAA AGGTTGGGGT

1681 AGGAAGATCA CTTGAGGCCA GGAGTTGGAG ACCAGCCTGG GAAACATGGC CAGCCCCCAC

1741 TCCCCGTCTC TACAAAAAAT TTAAAAATTG GCCAGGGAGG GTGGTTCATG CCTATAATAC

1801 CAACACTTTG GAAGGTTGAG GTGAGTGAAT TGCTTGAGCC CAGGAGTTAG TGACCAGCCT

1861 GGCCAATGTG GTAAAACCCG GTCTTTACTA AAAATACAAA AAATTAGCCA GGTGCGGTGT

1921 CGGCGCGCGC CTGTAATCCC AGCTACTCAG GAGGCTGAGG CGCGAGAATT GCTTGAACCC

1981 GGGAGGTGGA GGTTGCAGTG AGCCGAGATC ACGCCATTGC ACTTCCAGCC TGGGCACCAG

2041 AGCAAGACTG TCTCAAAAAG AAAAAAAAAA AAAAAAAA

B: aminoacid sequence (SEQ ID NO:20) length: 489 amino acid

1 MAPTLATAHR RRWWMACTPV LENLLFSAVL LGWGSLLIML KSEGFYSYLC TEPENVTNGT

61 VGGTAEPGHE EVSWMNGWLS CQAQDEMLNL AFTVGSFLLS AITLPLGIVM DKYGPRKLRL

121 LGSACFAVSC LLIAYGASKP NALSVLIFIA LALNGFGGMC MTFTSLTLPN MFGDLRSTFI

181 ALMIGSYASS AVTFPGIKLI YDAGVSFIVV LVVWAGCSGL VFLNCFFNWP LEPFPGPEDM

241 DYSVKIKFSW LGFDHKITGK QFYKQVTTVG RRLSVGSSMR SAKEQVALQE GHKLCLSTVD

301 LEVKCQPDAA VAPSFMHSVF SPILLLSLVT MCVTQLRLIF YMGAMNNILK FLVSGDQKTV

361 GLYTSIFGVL QLLCLLTAPV IGYIMDWRLK ECEDASEEPE EKDANQCVGR AGAPAPSPQP

421 LQKDPRAACQ AQGGWDRGRE QCTPAPPGAL REAHSFSSAC VSTAPLFMEI VWNAMEMLEF

481 EARCGDSCL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:21)

Clone number: PP7664

Start code: 185ATG stops coding: 1652TAA

Protein molecular weight: 53338.39

1 G GCA GGC CAG GAC TAG TTC CAC GGC CCT GAG CAT GCG TTA GCC CCT 46

47 TCT TGC CTC CAT GCA TCA GTT TAC CTC GGA GTG AGC TGC GGG AGA CGT 94

95 CTC CCT GCC TGG CCG GGG CGG CTC TGT CGT AGC GGA GGG CAG CGG TGG 142

143 TGC AGA TCC GGA GCC GGA GCC GGA GCC GCG CCG CGC CGC ACC ATG GCG 190

1 Met Ala 2

191 CCC ACC CTG GCC ACT GCC CAT CGG CGC CGC TGG TGG ATG GCC TGC ACG 238

3 Pro Thr Leu Ala Thr Ala His Arg Arg Arg Trp Trp Met Ala Cys Thr 18

239 CCC GTG CTG GAG AAC CTC CTC TTC TCG GCA GTC CTC CTG GGC TGG GGC 286

19 Pro Val Leu Glu Asn Leu Leu Phe Ser Ala Val Leu Leu Gly Trp Gly 34

287 TCG CTG CTC ATC ATG CTC AAG TCA GAG GGC TTT TAC TCC TAC CTG TGT 334

35 Ser Leu Leu Ile Met Leu Lys Ser Glu Gly Phe Tyr Ser Tyr Leu Cys 50

335 ACC GAG CCA GAG AAT GTC ACC AAT GGC ACA GTG GGC GGC ACA GCA GAG 382

51 Thr Glu Pro Glu Asn Val Thr Asn Gly Thr Val Gly Gly Thr Ala Glu 66

383 CCG GGG CAC GAG GAG GTG AGC TGG ATG AAC GGC TGG CTC AGC TGC CAG 430

67 Pro Gly His Glu Glu Val Ser Trp Met Asn Gly Trp Leu Ser Cys Gln 82

431 GCC CAG GAC GAG ATG CTA AAT TTG GCC TTC ACT GTG GGC TCC TTT CTG 478

83 Ala Gln Asp Glu Met Leu Asn Leu Ala Phe Thr Val Gly Ser Phe Leu 98

479 CTC AGT GCC ATC ACC CTG CCC CTG GGT ATC GTC ATG GAC AAG TAT GGC 526

99 Leu Ser Ala Ile Thr Leu Pro Leu Gly Ile Val Met Asp Lys Tyr Gly 114

527 CCG AGG AAG CTC AGG CTG CTG GGC AGC GCC TGC TTC GCG GTT TCC TGC 574

115 Pro Arg Lys Leu Arg Leu Leu Gly Ser Ala Cys Phe Ala Val Ser Cys 130

575 TTG CTG ATT GCG TAC GGA GCA AGT AAA CCA AAC GCT CTC TCC GTG CTC 622

131 Leu Leu Ile Ala Tyr Gly Ala Ser Lys Pro Asn Ala Leu Ser Val Leu 146

623 ATC TTC ATC GCC CTG GCT CTG AAT GGC TTT GGT GGG ATG TGT ATG ACC 670

147 Ile Phe Ile Ala Leu Ala Leu Asn Gly Phe Gly Gly Met Cys Met Thr 162

671 TTC ACC TCA TTA ACA CTG CCC AAC ATG TTC GGC GAC CTT CGG TCC ACG 718

163 Phe Thr Ser Leu Thr Leu Pro Asn Met Phe Gly Asp Leu Arg Ser Thr 178

719 TTT ATT GCC TTG ATG ATT GGG TCC TAC GCC TCC TCG GCA GTC ACC TTT 766

179 Phe Ile Ala Leu Met Ile Gly Ser Tyr Ala Ser Ser Ala Val Thr Phe 194

767 CCA GGA ATC AAG CTC ATC TAT GAT GCT GGT GTC TCC TTC ATC GTC GTC 814

195 Pro Gly Ile Lys Leu Ile Tyr Asp Ala Gly Val Ser Phe Ile Val Val 210

815 CTC GTG GTC TGG GCC GGC TGC TCC GGG CTG GTT TTC CTC AAC TGC TTC 862

211 Leu Val Val Trp Ala Gly Cys Ser Gly Leu Val Phe Leu Asn Cys Phe 226

863 TTT AAC TGG CCC CTT GAG CCC TTC CCG GGG CCG GAG GAC ATG GAC TAC 910

227 Phe Asn Trp Pro Leu Glu Pro Phe Pro Gly Pro Glu Asp Met Asp Tyr 242

911 TCG GTG AAG ATC AAG TTC AGC TGG CTG GGC TTT GAC CAC AAG ATC ACA 958

243 Ser Val Lys Ile Lys Phe Ser Trp Leu Gly Phe Asp His Lys Ile Thr 258

959 GGG AAG CAG TTC TAC AAG CAG GTG ACC ACG GTG GGC CGG CGC CTG AGT 1006

259 Gly Lys Gln Phe Tyr Lys Gln Val Thr Thr Val Gly Arg Arg Leu Ser 274

1007 GTG GGC AGC TCC ATG AGG AGT GCC AAG GAG CAG GTG GCG CTG CAG GAG 1054

275 Val Gly Ser Ser Met Arg Ser Ala Lys Glu Gln Val Ala Leu Gln Glu 290

1055 GGC CAC AAG CTG TGC CTG TCC ACC GTC GAC CTG GAG GTG AAG TGC CAG 1102

291 Gly His Lys Leu Cys Leu Ser Thr Val Asp Leu Glu Val Lys Cys Gln 306

1103 CCG GAT GCC GCA GTG GCC CCC TCC TTC ATG CAC AGC GTG TTC AGC CCC 1150

307 Pro Asp Ala Ala Val Ala Pro Ser Phe Met His Ser Val Phe Ser Pro 322

1151 ATC CTG CTG CTC AGC CTG GTC ACC ATG TGC GTC ACG CAG CTG CGG CTC 1198

323 Ile Leu Leu Leu Ser Leu Val Thr Met Cys Val Thr Gln Leu Arg Leu 338

1199 ATC TTC TAC ATG GGG GCT ATG AAC AAC ATC CTC AAG TTC CTG GTCAGC 1246

339 Ile Phe Tyr Met Gly Ala Met Asn Asn Ile Leu Lys Phe Leu Val Ser 354

1247 GGC GAC CAG AAG ACA GTT GGC CTC TAC ACC TCC ATC TTC GGC GTG CTC 1294

355 Gly Asp Gln Lys Thr Val Gly Leu Tyr Thr Ser Ile Phe Gly Val Leu 370

1295 CAG CTG CTG TGC CTG CTG ACG GCC CCC GTC ATT GGC TAC ATC ATG GAC 1342

371 Gln Leu Leu Cys Leu Leu Thr Ala Pro Val Ile Gly Tyr Ile Met Asp 386

1343 TGG AGG CTG AAG GAG TGT GAA GAC GCC TCC GAG GAG CCC GAG GAG AAA 1390

387 Trp Arg Leu Lys Glu Cys Glu Asp Ala Ser Glu Glu Pro Glu Glu Lys 402

1391 GAC GCC AAC CAG TGC GTA GGC AGG GCC GGT GCC CCG GCT CCC AGC CCG 1438

403 Asp Ala Asn Gln Cys Val Gly Arg Ala Gly Ala Pro Ala Pro Ser Pro 418

1439 CAG CCC CTG CAG AAA GAC CCC AGA GCT GCA TGT CAG GCA CAG GGT GGG 1486

419 Gln Pro Leu Gln Lys Asp Pro Arg Ala Ala Cys Gln Ala Gln Gly Gly 434

1487 TGG GAC AGA GGG AGA GAG CAA TGC ACT CCA GCT CCT CCC GGA GCC CTT 1534

435 Trp Asp Arg Gly Arg Glu Gln Cys Thr Pro Ala Pro Pro Gly Ala Leu 450

1535 AGA GAG GCT CAC TCA TTC AGC TCA GCA TGC GTT TCA ACT GCT CCC CTC 1582

451 Arg Glu Ala His Ser Phe Ser Ser Ala Cys Val Ser Thr Ala Pro Leu 466

1583 TTT ATG GAA ATT GTT TGG AAT GCA ATG GAA ATG CTA GAG TTT GAG GCC 1630

467 Phe Met Glu Ile Val Trp Asn Ala Met Glu Met Leu Glu Phe Glu Ala 482

1631 AGG TGC GGT GAC TCA TGC CTG TAA TCC CAA GCA CTT TGA AAG GTT GGG 1678

483 Arg Cys Gly Asp Ser Cys Leu *** 490

1679 GTA GGA AGA TCA CTT GAG GCC AGG AGT TGG AGA CCA GCC TGG GAA ACA 1726

1727 TGG CCA GCC CCC ACT CCC CGT CTC TAC AAA AAA TTT AAA AAT TGG CCA 1774

1775 GGG AGG GTG GTT CAT GCC TAT AAT ACC AAC ACT TTG GAA GGT TGA GGT 1822

1823 GAG TGA ATT GCT TGA GCC CAG GAG TTA GTG ACC AGC CTG GCC AAT GTG 1870

1871 GTA AAA CCC GGT CTT TAC TAA AAA TAC AAA AAA TTA GCC AGG TGC GGT 1918

1919 GTC GGC GCG CGC CTG TAA TCC CAG CTA CTC AGG AGG CTG AGG CGC GAG 1966

1967 AAT TGC TTG AAC CCG GGA GGT GGA GGT TGC AGT GAG CCG AGA TCA CGC 2014

2015 CAT TGC ACT TCC AGC CTG GGC ACC AGA GCA AGA CTG TCT CAA AAA GAA 2062

2063 AAA AAA AAA AAA AAA A 2078

8.PP7827

A: nucleotide sequence (SEQ ID NO:22) length: 2498bp

l GTTTTATTGC CACAACTAAC CTCCTCGGAC TCCTGCCTCA CTCATTTACA CCAACCACCC

61 AACTATCTAT AAACCTAGCC ATGGCCATCC CCTTATGAGC GGGCGCAGTG ATTATAGGCT

12l TTCGCTCTAA GATTAAAAAT GCCCTAGCCC ACTTCTTACC ACAAGGCACA CCTACACCCC

181 TTATCCCCAT ACTAGTTATT ATCGAAACCA TCAGCCTACT CATTCAACCA ATAGCCCTGG

241 CCGTACGCCT AACCGTAACA TTACTGCAGG CCACCTACTC ATGCACCTAA TTGGAAGCGC

301 CACCCTAGCA ATATCAACCA TTAACCTTCC CTCTACACTT ATCATCTTGA CAATTCTAAT

361 TCTACTGACT ATCCTAGAAA TCGCTGTCGC TTAATCCAAG CCTACGTTTT CACACTTCTA

421 GTAAGCCTCT ACCTGCACGA CAACACATAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

481 AAAAAAAAAA AAAAAAAAAA AAAAAAACCT TCCCCGCGCC GGCCGGGTCC CGCCCGTTCC

541 CCGGCACCAG AAGTTCCTTT GCGCGTCCGA CGGCGACATG GGCGTCCCCA CGGCCCTGGA

601 GGCCGGCAGC TGGCGCTGGG GATCCCTGCT CTTCGCTCTT TTCCTGGCTG CGTCCCTAGG

661 TCCGGTGGCA GCCTTAAAGG TCGCCACGCC GTATTCCCTG TATGTCTGTC CCGAGGGGCA

721 AAACGTCACC CTCACCTGCA GGCTTTTGGG CCCTGTGGAC AAAGGGCACG ATGTGACCTT

781 CTACAAGACG TGGTACCGCA GCTCGAGGGG CGAGGTGCAA ACCTGTTAAA AGCGCCGGCC

841 CATCCGAAAC CTAACGTTCC AGGACCTTCA CCTGCACCAT GGAGGCCACC AGGCTGCCAA

901 CACCAGCCAC GACCTGGCTC AGCGCCACGG GCTGGAGTCG GCCTCCGACC ACCATGGCAA

961 CTTCTCCATC ACCATGCGCA ACCTGACCCT GCTGGATAGC GGCCTCTACT GCTGCCTGGT

1021 GGTGGAGATC AGGCACCACC ACTCGGAGCA CAGGGTCCAT GGTGCCATGG AGCTGCAGGT

1081 GCAGACAGGC AAAGATGCAC CATCCAACTG TGTGGTGTAC CCATCCTCCT CCCAGGAGAG

1141 TGAAAACATC ACGGCTGCAG CCCTGGCTAC GGGTGCCTGC ATCGTAGGAA TCCTCTGCCT

1201 CCCCCTCATC CTGCTCCTGG TCTACAAGCA AAGGCAGGCA GCCTCCAACC GCCGTGCCCA

1261 GGAGCTGGTG CGGATGGACA GCAACATTCA AGGGATTGAA AACCCCGGCT TTGAAGCCTC

1321 ACCACCTGCC CAGGGGATAC CCGAGGCCAA AGTCAGGCAC CCCCTGTCCT ATGTGGCCCA

1381 GCGGCAGCCT TCTGAGTCTG GGCGGCATCT GCTTTCGGAG CCCAGCACCC CCCTGTCTCC

1441 TCCAGGCCCC GGAGACGTCT TCTTCCCATC CCTGGACCCT GTCCCTGACT CTCCAAACTT

1501 TGAGGTCATC TAGCCCAGCT GGGGGACAGT GGGCTGTTGT GGCTGGGTCT GGGGCAGGTG

1561 CATTTGAGCC AGGGCTGGCT CTGTGAGTGG CCTCCTTGGC CTCGGCCCTG GTTCCCTCCC

1621 TCCTGCTCTG GGCTCAGATA CTGTGACATC CCAAAAGCCC AGCCCCTCAA CCCCTCTGGA

1681 TGCTACATGG GGATGCTGGA CGGCTCAGCC CCTGTTCCAA GGATTTTGGG GTGCTGAGAT

1741 TCTCCCCTAG AGACCTGAAA TTCACCAGCT ACAGATGCCA AATGACTTAC ATCTTAAGAA

1801 GTCTCAAAAC GTCCAGCCCT TCAGCAGCTC TCGTTCTGAG ACATGAGCCT TGGGATGTGG

1861 CAGCATCAGT GGGACAAGAT GGACACTGGG CCACCCTCCC AGGCACCAGA CACAGGGCAC

1921 GGTGGAGAGA CTTCTCCCCC GTGGCCGCCT TGGCTCCCCC GTTTTGCCCG AGGCTGCTCT

1981 TCTGTCAGAC TTCCTCTTTG TACCACAGTG GCTCTGGGGC CAGGCCTGCC TGCCCACTGG

2041 CCATCGCCAC CTTCCCCAGC TGCCTCCTAC CAGCAGTTTC TCTGAAGATC TGTCAACAGG

2101 TTAAGTCAAT CTGGGGCTTC CACTGCCTGC ATTCCAGTCC CCAGAGCTTG GTGGTCCCGA

2161 AACGGGAAGT ACATATTGGG GCATGGTGGC CTCCGTGAGC AAATGGTGTC TTGGGCAATC

2221 TGAGGCCAGG ACAGATGTTG CCCCACCCAC TGGAGATGGT GCTGAGGGAG GTGGGTGGGG

2281 CCTTCTGGGA AGGTGAGTGG AGAGGGGCAC CTGCCCCCCG CCCTCCCCAT CCCCTACTCC

2341 CACTGCTCAG CGCGGGCCAT TGCAAGGGTG CCACACAATG TCTTGTCCAC CCTGGGACAC

2401 TTCTGAGTAT GAAGCGGGAT GCTATTAAAA ACTACATGGG GAAACAGGTG CAAAAAAAAA

2461 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAA

B: aminoacid sequence (SEQ ID NO:23) length: 179 amino acid

1 MRNLTLLDSG LYCCLVVEIR HHHSEHRVHG AMELQVQTGK DAPSNCVVYP SSSQESENIT

61 AAALATGACI VGILCLPLIL LLVYKQRQAA SNRRAQELVR MDSNIQGIEN PGFEASPPAQ

121 GIPEAKVRHP LSYVAQRQPS ESGRHLLSEP STPLSPPGPG DVFFPSLDPV PDSPNFEVI

C. Nucleotide and amino acid composite sequence (SEQ ID NO:24)

Clone number: PP7827

Start code: 974ATG stops coding: 1511TAG

Protein molecular weight: 19394.03

1 G TTT TAT TGC CAC AAC TAA CCT CCT CGG ACT CCT GCC TCA CTC ATT 46

47 TAC ACC AAC CAC CCA ACT ATC TAT AAA CCT AGC CAT GGC CAT CCC CTT 94

95 ATG AGC GGG CGC AGT GAT TAT AGG CTT TCG CTC TAA GAT TAA AAA TGC 142

143 CCT AGC CCA CTT CTT ACC ACA AGG CAC ACC TAC ACC CCT TAT CCC CAT 190

191 ACT AGT TAT TAT CGA AAC CAT CAG CCT ACT CAT TCA ACC AAT AGC CCT 238

239 GGC CGT ACG CCT AAC CGT AAC ATT ACT GCA GGC CAC CTA CTC ATG CAC 286

287 CTA ATT GGA AGC GCC ACC CTA GCA ATA TCA ACC ATT AAC CTT CCC TCT 334

335 ACA CTT ATC ATC TTG ACA ATT CTA ATT CTA CTG ACT ATC CTA GAA ATC 382

383 GCT GTC GCT TAA TCC AAG CCT ACG TTT TCA CAC TTC TAG TAA GCC TCT 430

431 ACC TGC ACG ACA ACA CAT AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 478

479 AAA AAA AAA AAA AAA AAA AAA AAA AAA AAC CTT CCC CGC GCC GGC CGG 526

527 GTC CCG CCC GTT CCC CGG CAC CAG AAG TTC CTT TGC GCG TCC GAC GGC 574

575 GAC ATG GGC GTC CCC ACG GCC CTG GAG GCC GGC AGC TGG CGC TGG GGA 622

623 TCC CTG CTC TTC GCT CTT TTC CTG GCT GCG TCC CTA GGT CCG GTG GCA 670

671 GCC TTA AAG GTC GCC ACG CCG TAT TCC CTG TAT GTC TGT CCC GAG GGG 718

719 CAA AAC GTC ACC CTC ACC TGC AGG CTT TTG GGC CCT GTG GAC AAA GGG 766

767 CAC GAT GTG ACC TTC TAC AAG ACG TGG TAC CGC AGC TCG AGG GGC GAG 814

815 GTG CAA ACC TGT TAA AAG CGC CGG CCC ATC CGA AAC CTA ACG TTC CAG 862

863 GAC CTT CAC CTG CAC CAT GGA GGC CAC CAG GCT GCC AAC ACC AGC CAC 910

911 GAC CTG GCT CAG CGC CAC GGG CTG GAG TCG GCC TCC GAC CAC CAT GGC 958

959 AAC TTC TCC ATC ACC ATG CGC AAC CTG ACC CTG CTG GAT AGC GGC CTC 1006

1 Met Arg Asn Leu Thr Leu Leu Asp Ser Gly Leu 11

1007 TAC TGC TGC CTG GTG GTG GAG ATC AGG CAC CAC CAC TCG GAG CAC AGG 1054

12 Tyr Cys Cys Leu Val Val Glu Ile Arg His His His Ser Glu His Arg 27

1055 GTC CAT GGT GCC ATG GAG CTG CAG GTG CAG ACA GGC AAA GAT GCA CCA 1102

28 Val His Gly Ala Met Glu Leu Gln Val Gln Thr Gly Lys Asp Ala Pro 43

1103 TCC AAC TGT GTG GTG TAC CCA TCC TCC TCC CAG GAG AGT GAA AAC ATC 1150

44 Ser Asn Cys Val Val Tyr Pro Ser Ser Ser Gln Glu Ser Glu Asn Ile 59

1151 ACG GCT GCA GCC CTG GCT ACG GGT GCC TGC ATC GTA GGA ATC CTC TGC 1198

60 Thr Ala Ala Ala Leu Ala Thr Gly Ala Cys Ile Val Gly Ile Leu Cys 75

1199 CTC CCC CTC ATC CTG CTC CTG GTC TAC AAG CAA AGG CAG GCA GCC TCC 1246

76 Leu Pro Leu Ile Leu Leu Leu Val Tyr Lys Gln Arg Gln Ala Ala Ser 91

1247 AAC CGC CGT GCC CAG GAG CTG GTG CGG ATG GAC AGC AAC ATT CAA GGG 1294

92 Asn Arg Arg Ala Gln Glu Leu Val Arg Met Asp Ser Asn Ile Gln Gly 107

1295 ATT GAA AAC CCC GGC TTT GAA GCC TCA CCA CCT GCC CAG GGG ATA CCC 1342

108 Ile Glu Asn Pro Gly Phe Glu Ala Ser Pro Pro Ala Gln Gly Ile Pro 123

1343 GAG GCC AAA GTC AGG CAC CCC CTG TCC TAT GTG GCC CAG CGG CAG CCT 1390

124 Glu Ala Lys Val Arg His Pro Leu Ser Tyr Val Ala Gln Arg Gln Pro 139

1391 TCT GAG TCT GGG CGG CAT CTG CTT TCG GAG CCC AGC ACC CCC CTG TCT 1438

140 Ser Glu Ser Gly Arg His Leu Leu Ser Glu Pro Ser Thr Pro Leu Ser 155

1439 CCT CCA GGC CCC GGA GAC GTC TTC TTC CCA TCC CTG GAC CCT GTC CCT 1486

156 Pro Pro Gly Pro Gly Asp Val Phe Phe Pro Ser Leu Asp Pro Val Pro 171

1487 GAC TCT CCA AAC TTT GAG GTC ATC TAG CCC AGC TGG GGG ACA GTG GGC 1534

172 Asp Ser Pro Asn Phe Glu Val Ile *** 180

1535 TGT TGT GGC TGG GTC TGG GGC AGG TGC ATT TGA GCC AGG GCT GGC TCT 1582

1583 GTG AGT GGC CTC CTT GGC CTC GGC CCT GGT TCC CTC CCT CCT GCT CTG 1630

1631 GGC TCA GAT ACT GTG ACA TCC CAA AAG CCC AGC CCC TCA ACC CCT CTG 1678

1679 GAT GCT ACA TGG GGA TGC TGG ACG GCT CAG CCC CTG TTC CAA GGA TTT 1726

1727 TGG GGT GCT GAG ATT CTC CCC TAG AGA CCT GAA ATT CAC CAG CTA CAG 1774

1775 ATG CCA AAT GAC TTA CAT CTT AAG AAG TCT CAA AAC GTC CAG CCC TTC 1822

1823 AGC AGC TCT CGT TCT GAG ACA TGA GCC TTG GGA TGT GGC AGC ATC AGT 1870

1871 GGG ACA AGA TGG ACA CTG GGC CAC CCT CCC AGG CAC CAG ACA CAG GGC 1918

1919 ACG GTG GAG AGA CTT CTC CCC CGT GGC CGC CTT GGC TCC CCC GTT TTG 1966

1967 CCC GAG GCT GCT CTT CTG TCA GAC TTC CTC TTT GTA CCA CAG TGG CTC 2014

2015 TGG GGC CAG GCC TGC CTG CCC ACT GGC CAT CGC CAC CTT CCC CAG CTG 2062

2063 CCT CCT ACC AGC AGT TTC TCT GAA GAT CTG TCA ACA GGT TAA GTC AAT 2110

2111 CTG GGG CTT CCA CTG CCT GCA TTC CAG TCC CCA GAG CTT GGT GGT CCC 2158

2159 GAA ACG GGA AGT ACA TAT TGG GGC ATG GTG GCC TCC GTG AGC AAA TGG 2206

2207 TGT CTT GGG CAA TCT GAG GCC AGG ACA GAT GTT GCC CCA CCC ACT GGA 2254

2255 GAT GGT GCT GAG GGA GGT GGG TGG GGC CTT CTG GGA AGG TGA GTG GAG 2302

2303 AGG GGC ACC TGC CCC CCG CCC TCC CCA TCC CCT ACT CCC ACT GCT CAG 2350

2351 CGC GGG CCA TTG CAA GGG TGC CAC ACA ATG TCT TGT CCA CCC TGG GAC 2398

2399 ACT TCT GAG TAT GAA GCG GGA TGC TAT TAA AAA CTA CAT GGG GAA ACA 2446

2447 GGT GCA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 2494

2495 AAA A 2498

9.PP7882

A: nucleotide sequence (SEQ ID NO:25) length: 2383bp

1 GTCAGTCTCC GCCTGCCCTG ACTGCGCCCT CCCACGCAGA CACGGGACTC AATCCGCGCC

61 TCGGCCGTCG GGCTCCTTGG GACTCTGGTG CGCCGGGGCC GGGGCGGGCT CCGGCTGGGG

121 CTCCGCGGCC CCCTGCGGAA GCTGGTGCTG CAGAGTCTCG TGCCGCTGCT GCTGCGCCTG

181 CATGACCCCA GCAGGGACGC TGCTGAGGTC AGCAGCCCCC GACACCATCC CACCCCTATG

241 CCATCCAACA CTCACCACTC CCACCGTGCC TCCCCTCCGA CAATTACAGG TCAGGGACTC

301 ACCCATCCCA AGGACCTCAG TGGCAGGTGT GACGGGCGGC CAGGTTACTA CTGCTCTTCC

361 CTTGAGCAGA ATCAATCCGG TTTCCTGCCC TGGGCTCTTC TGCCCCTCAC CCGATGCCTT

421 TGCTCCCCCT CTTCCCACCC CAACTTTTGC CTTTTTACTT CCTGGACCCC TGACCCGGCT

481 CACTTCCCCT ATCCCAGAGC TCAGAGTGGA CCCTGGCCCG CTGTGACCAC GCCTTTTGCT

541 GGGGCCTGCT GGAGGAGTTG GTCACCGTGG CCCACTATGA CAGCCCCGAG GCCCTGAGCC

601 ACCTCTGCTG CCGCCTGGTC AGTAGGGGAA GCAAGGTGAC CGCAAGGGGG TATGATCAGC

661 AGCCCACTTG TTCCAGGGTT CACCGGGGCC CCCAACCGTT TCTACTGCAG CCAAACCAGA

721 TAGGCTACTG GTGGGGCAAG TCCAAGGTCT CCGACCATGC CACCTGCCCT GGGGGCTCCC

781 CTGGAACCCC GGCCCCTGGA TTCAGCTCTG CAGCCTCCTC CGCACTCAGG ATCAGCCCTC

841 CTGTCCTGCC ACTAGCCCTT TTGTCCCCAG GTTCAGCGAT ACCCAGGCCA CGTGCCCAAC

901 TTCCTGAGCC AGACCCAGGG CTACCTGCGG AGTCCACAGG ACCCCCTGCG CCGGGCAGCC

961 ACCGTGCTTA TAGGCTTCCT TGTCCACCAC GCCAGCCCCG GCTGTGTCAA CCAGGACCTG

1021 CTGGACTCCC TGTTCCAGGA CCTAGGGCGG CTGCAGAGCG ACCCCAAGCC GGCCGTGGCC

1081 GCGGCAGCGC ACGTGTCCGC TCAGCAGGTG GCGATGCTGG CCCGCGCCCG GGGCTGCCCC

1141 CGCGGGCCCC GCCTTCTCCG CATCGCCCCG CGCCCCGCCC GGCCCCCACC AGTCTTCGCC

1201 GACAGCCCCT TCCAGCGCCG GAGCGTCGCG GGCCGCTGGG GCTGCTCCGG ACCCCGCCGA

1261 GCCTGAGGCT CGGGGCTGGG GCCCGAGGGC CAGGGTCCGA CTCGGGCACC CCACGCGCAT

1321 AGCAGCCTGT CCCCGCCCTG ACGGAGGGGC TCCCTGGGCC TGGTGCTGGA CGCCAATGCC

1381 CTCCCCCACC CCCCACCCCC GTGACCCCTG TTCAGGCACC CGCCACCCTG ATGGTGACAG

1441 AGGGGGACAG CCAGCACCCA TCTGTCCCCG TCAGGGCTCT TGCTCTCACA GCCCCCTGGA

1501 GCATGCCCCA TGCCCCAACC TTGGGCCTGG CTCCTGGCCC AGATGGCACC TGGCCTCTTG

1561 AGTCTGCTGG GGGACCCCAA AGTTGGTGGT CCCATAGCCT GCCCTCCTGG GTCTCCACCT

1621 CATGCCTGGA CAGGACGCTG TGGCCTGTCC GGGCCTTGGC CAGCCCTGCA GCTGCACCCC

1681 CGATCCTCAT CCCTCACCCC ATTCCCTGCC AGCATCCTAA GGCTCCTGGC GGGCATCCTC

1741 TCTGCTCAAA ATTATTGACC TGTCTCCCGG CCACACCTGC TGTGCCCTCT CAGCCAGGCC

1801 ATCATCACCC CCTGTTCATT ATGTCAGGCC TCATGGGAGC CTGGCCTTCT CCAGAAGCTG

1861 GCCCCGGCGT CCTCCCAAGC TGGACCACGT AGGCCCCAGA TCACACCTGG GGGTCCAGAT

1921 GTAGGGGTCC CGTGTGCACG CCCAATCAGA CCGAGCACTT GTGACACTAC CCCAACACCT

1981 CTCCCAGGGC TGAATGAGGA ACGCGCCACT GGACACATGA GGAAGAGGCT GCCCTGGGAG

2041 CTACTGATGC TGTGACCTCA CCTCTCTGGC TTTGGGCGGC AGGTCCCTGC ACCTAGGATG

2101 CCTGCCTGGA AATGTCCTTG CATTCGTGGC CTCCTTCACA GCCTCCTCCT CAGAGAAGCC

2161 TCTGCGAGTG CACAGGGAGT GTGTGCAGCC TTGTGAAGGG CTGGGACCAC TTGCCCAGAC

2221 TGGGGCCCCT CAGGCACAGG CGTGGGGTCC TACTGACCTG TCTCCCCAGC TCCCACACAG

2281 AAAGCATCTA AAATAAACAC ACGTGGATGG AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

2341 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAA

B: aminoacid sequence (SEQ ID NO:26) length: 153 amino acid

1 MVTEGDSQHP SVPVRALALT APWSMPHAPT LGLAPGPDGT WPLESAGGPQ SWWSHSLPSW

61 VSTSCLDRTL WPVRALASPA AAPPILIPHP IPCQHPKAPG GHPLCSKLLT CLPATPAVPS

121 QPGHHHPLFI MSGLMGAWPS PEAGPGVLPS WTT

C. Nucleotide and amino acid composite sequence (SEQ ID NO:27)

Clone number: PP7882

Start code: 1431ATG stops coding: 1890TAG

Protein molecular weight: 15965.48

1 GT CAG TCT CCG CCT GCC CTG ACT GCG CCC TCC CAC GCA GAC ACG GGA 47

48 CTC AAT CCG CGC CTC GGC CGT CGG GCT CCT TGG GAC TCT GGT GCG CCG 95

96 GGG CCG GGG CGG GCT CCG GCT GGG GCT CCG CGG CCC CCT GCG GAA GCT 143

144 GGT GCT GCA GAG TCT CGT GCC GCT GCT GCT GCG CCT GCA TGA CCC CAG 191

192 CAG GGA CGC TGC TGA GGT CAG CAG CCC CCG ACA CCA TCC CAC CCC TAT 239

240 GCC ATC CAA CAC TCA CCA CTC CCA CCG TGC CTC CCC TCC GAC AAT TAC 287

288 AGG TCA GGG ACT CAC CCA TCC CAA GGA CCT CAG TGG CAG GTG TGA CGG 335

336 GCG GCC AGG TTA CTA CTG CTC TTC CCT TGA GCA GAA TCA ATC CGG TTT 383

384 CCT GCC CTG GGC TCT TCT GCC CCT CAC CCG ATG CCT TTG CTC CCC CTC 431

432 TTC CCA CCC CAA CTT TTG CCT TTT TAC TTC CTG GAC CCC TGA CCC GGC 479

480 TCA CTT CCC CTA TCC CAG AGC TCA GAG TGG ACC CTG GCC CGC TGT GAC 527

528 CAC GCC TTT TGC TGG GGC CTG CTG GAG GAG TTG GTC ACC GTG GCC CAC 575

576 TAT GAC AGC CCC GAG GCC CTG AGC CAC CTC TGC TGC CGC CTG GTC AGT 623

624 AGG GGA AGC AAG GTG ACC GCA AGG GGG TAT GAT CAG CAG CCC ACT TGT 671

672 TCC AGG GTT CAC CGG GGC CCC CAA CCG TTT CTA CTG CAG CCA AAC CAG 719

720 ATA GGC TAC TGG TGG GGC AAG TCC AAG GTC TCC GAC CAT GCC ACC TGC 767

768 CCT GGG GGC TCC CCT GGA ACC CCG GCC CCT GGA TTC AGC TCT GCA GCC 815

816 TCC TCC GCA CTC AGG ATC AGC CCT CCT GTC CTG CCA CTA GCC CTT TTG 863

864 TCC CCA GGT TCA GCG ATA CCC AGG CCA CGT GCC CAA CTT CCT GAG CCA 911

912 GAC CCA GGG CTA CCT GCG GAG TCC ACA GGA CCC CCT GCG CCG GGC AGC 959

960 CAC CGT GCT TAT AGG CTT CCT TGT CCA CCA CGC CAG CCC CGG CTG TGT 1007

1008 CAA CCA GGA CCT GCT GGA CTC CCT GTT CCA GGA CCT AGG GCG GCT GCA 1055

1056 GAG CGA CCC CAA GCC GGC CGT GGC CGC GGC AGC GCA CGT GTC CGC TCA 1103

1104 GCA GGT GGC GATGCT GGC CCG CGC CCG GGG CTG CCC CCG CGG GCC CCG 1151

1152 CCT TCT CCG CAT CGC CCC GCG CCC CGC CCG GCC CCC ACC AGT CTT CGC 1199

1200 CGA CAG CCC CTT CCA GCG CCG GAG CGT CGC GGG CCG CTG GGG CTG CTC 1247

1248 CGG ACC CCG CCG AGC CTG AGG CTC GGG GCT GGG GCC CGA GGG CCA GGG 1295

1296 TCC GAC TCG GGC ACC CCA CGC GCA TAG CAG CCT GTC CCC GCC CTG ACG 1343

1344 GAG GGG CTC CCT GGG CCT GGT GCT GGA CGC CAA TGC CCT CCC CCA CCC 1391

1392 CCC ACC CCC GTG ACC CCT GTT CAG GCA CCC GCC ACC CTG ATG GTG ACA 1439

1 Met Val Thr 3

1440 GAG GGG GAC AGC CAG CAC CCA TCT GTC CCC GTC AGG GCT CTT GCT CTC 1487

4 Glu Gly Asp Ser Gln His Pro Ser Val Pro Val Arg Ala Leu Ala Leu 19

1488 ACA GCC CCC TGG AGC ATG CCC CAT GCC CCA ACC TTG GGC CTG GCT CCT 1535

20 Thr Ala Pro Trp Ser Met Pro His Ala Pro Thr Leu Gly Leu Ala Pro 35

1536 GGC CCA GAT GGC ACC TGG CCT CTT GAG TCT GCT GGG GGA CCC CAA AGT 1583

36 Gly Pro Asp Gly Thr Trp Pro Leu Glu Ser Ala Gly Gly Pro Gln Ser 51

1584 TGG TGG TCC CAT AGC CTG CCC TCC TGG GTC TCC ACC TCA TGC CTG GAC 1631

52 Trp Trp Ser His Ser Leu Pro Ser Trp Val Ser Thr Ser Cys Leu Asp 67

1632 AGG ACG CTG TGG CCT GTC CGG GCC TTG GCC AGC CCT GCA GCT GCA CCC 1679

68 Arg Thr Leu Trp Pro Val Arg Ala Leu Ala Ser Pro Ala Ala Ala Pro 83

1680 CCG ATC CTC ATC CCT CAC CCC ATT CCC TGC CAG CAT CCT AAG GCT CCT 1727

84 Pro Ile Leu Ile Pro His Pro Ile Pro Cys Gln His Pro Lys Ala Pro 99

1728 GGC GGG CAT CCT CTC TGC TCA AAA TTA TTG ACC TGT CTC CCG GCC ACA 1775

100 Gly Gly His Pro Leu Cys Ser Lys Leu Leu Thr Cys Leu Pro Ala Thr 115

1776 CCT GCT GTG CCC TCT CAG CCA GGC CAT CAT CAC CCC CTG TTC ATT ATG 1823

116 Pro Ala Val Pro Ser Gln Pro Gly His His His Pro Leu Phe Ile Met 131

1824 TCA GGC CTC ATG GGA GCC TGG CCT TCT CCA GAA GCT GGC CCC GGC GTC 1871

132 Ser Gly Leu Met Gly Ala Trp Pro Ser Pro Glu Ala Gly Pro Gly Val 147

1872 CTC CCA AGC TGG ACC ACG TAG GCC CCA GAT CAC ACC TGG GGG TCC AGA 1919

148 Leu Pro Ser Trp Thr Thr *** 154

1920 TGT AGG GGT CCC GTG TGC ACG CCC AAT CAG ACC GAG CAC TTG TGA CAC 1967

1968 TAC CCC AAC ACC TCT CCC AGG GCT GAA TGA GGA ACG CGC CAC TGG ACA 2015

2016 CAT GAG GAA GAG GCT GCC CTG GGA GCT ACT GAT GCT GTG ACC TCA CCT 2063

2064 CTC TGG CTT TGG GCG GCA GGT CCC TGC ACC TAG GAT GCC TGC CTG GAA 2111

2112 ATG TCC TTG CAT TCG TGG CCT CCT TCA CAG CCT CCT CCT CAG AGA AGC 2159

2160 CTC TGC GAG TGC ACA GGG AGT GTG TGC AGC CTT GTG AAG GGC TGG GAC 2207

2208 CAC TTG CCC AGA CTG GGG CCC CTC AGG CAC AGG CGT GGG GTC CTA CTG 2255

2256 ACC TGT CTC CCC AGC TCC CAC ACA GAA AGC ATC TAA AAT AAA CAC ACG 2303

2304 TGG ATG GAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 2351

2352 AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AA 2383

10.PP8038

A: nucleotide sequence (SEQ ID NO:28) length: 1828bp

1 GAGACAAGAA CCTGGCTGAA GAAAACTTGG TCCAAACTGC ATCAGAGGTG GGGGTGGTCG

61 CTGTTCCCAA GGGAAAGGTC CTGCTTAAAC AGGTGCTTTG TGAGTGGAAA CGTGGCCAGA

121 GTGCGGCGGG TGCTTTGTGA GTGGAAATGT GGCCAGAGTG CGGCGGATGC TTTGTGAGTG

181 GAAACGTGGC CTTCTCTGGA AGCCCTGGGG AGGGGCTTTC CGACTGAGAG GAAGGCCTCG

241 CATCTGCCCA CCGCCCAGTC CTGGGCCTCA CAGTGAGGAT GCAGGTCACG CTGCACAGAT

301 GAGGCCCGTG TGGCAGGTGG TCCCAGGAAC GAACTCGCCT CCCGCCAGCC CCCTGGGCCT

361 TCCATGGCCC CAGCCCCTTC CTATGCAGAC ACCCCTCACC CCTCTCTGGC CCTGCTTCAA

421 GCCCCCCTTC CCCGCCGTGT GGGCTTCTCG CTGTCCCCTA AGCCTTCGAT GTCCCCTCTG

481 AGCCACCGCG GCCACGGCCA ACAGGGATGC CTCCCTCACC AGCGCCTCCT GATAGCTCTG

541 GGCCTGAGCT CGGTAGAGAA ATGGAAGAGG AAGGTATATG CAGTGTTTGA CTGTCTCTGT

601 TTCTTGTCTC ACGTCACAAA ACAAGACTGA ATTTGGATTT CTGAACGCGA CTGTGTTTTC

661 CTCGGGAGGA TCTCTTGATC CCAGGAGGTA GAGGTTGCAG TGAGCCCAGA TCGCGCCACT

721 GCACTCCAGC CTGGGTGACA AAGCAGACTC TGTCTCGAAA AAACATACAT TGAAAAAGGC

781 AGAAGATTTG AACAGATACA TCAAAAAAAA GATAGACAAA TAGCAAATAA GCACTTGAAC

841 AGGTGCTCAG CATCGTTCGT TGTCAGAGGA ATGCACACGA AAACCGCAGC GACAGCGACT

901 AGAACAGCCA GGTGCTGAGG AGGGTGCGGA GCCCCTGGAA CTCACCCGTG CTGCTGAGAA

961 CACAAATGCT GCATCCGCTT TGGAAAGCAG CTTGGGAGTT GCATGTGAAA TTCAGCATTT

1021 ACCACACGGC CAGCAGTTCT GCTTTGGTTA TTCTACTCCA GAGTTTCCAC TGGGGGTCCT

1081 TTATGATTTC GTCTCTTCTA TCATTTTTTT GGTATAGATG GGGGTCTCGC TATTTGGATT

1141 ATTGTTGCAG GCGTGTTTGG GGTTTTTGAG TAGTGGTAGT GTCTGAGGTC AGTCAGGGTT

1201 GTTCTGGCCC CAGCAGGGCT CTTCGTAGCT TTTCCTGTGC AGGTGAACAA GCCTGCGGTT

1261 TCACTTGTTT CTCTTAACTT AAAGGAACTG TTGTTCCCAA GAGCAGTCTT GGGCTGAACT

1321 TTCAAATAAA ATGAGTTTCC TCAGGGAGCT TCAGAGCTCT TTCCTTATGG ACGGCCTCTC

1381 TCCCCAGGCT GATTTCTCTG CACCACCCTT CTGGGCACTG GGTAAGACAG CAGCCTCTGA

1441 TCTTCTTGGC CTGGCTTTCC CAGCATGGGT GCTCTACCCT ACTGTTTTAA CCTAGAAAGC

1501 CTGAACTGTA TTTAAAACTT GTGGTTTTTA AGGCCAGGCA CAGTGGCTCA TGCCTGTAAT

1561 CCCAGCACCT TGGGAAGCCA AGGTGGGTGG ATCACTTATG GTCAGGAGTT CAAGACCAGC

1621 CTGACCAACC TGGTGAAAGC CTGTCTCTAC TAAAAATATA AAAATAAGCC GGGCGTGGTG

1681 GCACATGCCT GTAATACCAG CTACCCAGGA AGCTGAGGCA GGAGAATTGC TTGAACCCAG

1741 GAGGCGGAGG TTGCAGTGAG CCAAGATGGC ACCACTGCAC TCCAGCCTGG GCGACAGCGA

1801 GACTCCATAT AAAAAAAAAA AAAAAAAA

B: aminoacid sequence (SEQ ID NO:29) length: 104 amino acid

1 MLCEWKRGLL WKPWGGAFRL RGRPRICPPP SPGPHSEDAG HAAQMRPVWQ VVPGTNSPPA

61 SPLGLPWPQP LPMQTPLTPL WPCFKPPFPA VWASRCPLSL RCPL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:30)

Clone number: PP8038

Start code: 167ATG stops coding: 479TGA

Protein molecular weight: 11558.07

1 G AGA CAA GAA CCT GGC TGA AGA AAA CTT GGT CCA AAC TGC ATC AGA 46

47 GGT GGG GGT GGT CGC TGT TCC CAA GGG AAA GGT CCT GCT TAA ACA GGT 94

95 GCT TTG TGA GTG GAA ACG TGG CCA GAG TGC GGC GGG TGC TTT GTG AGT 142

143 GGA AAT GTG GCC AGA GTG CGG CGG ATG CTT TGT GAG TGG AAA CGT GGC 190

1 Met Leu Cys Glu Trp Lys Arg Gly 8

191 CTT CTC TGG AAG CCC TGG GGA GGG GCT TTC CGA CTG AGA GGA AGG CCT 238

9 Leu Leu Trp Lys Pro Trp Gly GIy Ala Phe Arg Leu Arg Gly Arg Pro 24

239 CGC ATC TGC CCA CCG CCC AGT CCT GGG CCT CAC AGT GAG GAT GCA GGT 286

25 Arg Ile Cys Pro Pro Pro Ser Pro Gly Pro His Ser Glu Asp Ala Gly 40

287 CAC GCT GCA CAG ATG AGG CCC GTG TGG CAG GTG GTC CCA GGA ACG AAC 334

41 His Ala Ala Gln Met Arg Pro Val Trp Gln Val Val Pro Gly Thr Asn 56

335 TCG CCT CCC GCC AGC CCC CTG GGC CTT CCA TGG CCC CAG CCC CTT CCT 382

57 Ser Pro Pro Ala Ser Pro Leu Gly Leu Pro Trp Pro Gln Pro Leu Pro 72

383 ATG CAC ACA CCC CTC ACC CCT CTC TGG CCC TGC TTC AAG CCC CCC TTC 430

73 Met Gln Thr Pro Leu Thr Pro Leu Trp Pro Cys Phe Lys Pro Pro Phe 88

431 CCC GCC GTG TGG GCT TCT CGC TGT CCC CTA AGC CTT CGA TGT CCC CTC 478

89 Pro Ala Val Trp Ala Ser Arg Cys Pro Leu Ser Leu Arg Cys Pro Leu 104

479 TGA GCC ACC GCG GCC ACG GCC AAC AGG GAT GCC TCC CTC ACC AGC GCC 526

105 *** 105

527 TCC TGA TAG CTC TGG GCC TGA GCT CGG TAG AGA AAT GGA AGA GGA AGG 574

575 TAT ATG CAG TGT TTG ACT GTC TCT GTT TCT TGT CTC ACG TCA CAA AAC 622

623 AAG ACT GAA TTT GGA TTT CTG AAC GCG ACT GTG TTT TCC TCG GGA GGA 670

671 TCT CTT GAT CCC AGG AGG TAG AGG TTG CAG TGA GCC CAG ATC GCG CCA 718

719 CTG CAC TCC AGC CTG GGT GAC AAA GCA GAC TCT GTC TCG AAA AAA CAT 766

767 ACA TTG AAA AAG GCA GAA GAT TTG AAC AGA TAC ATC AAA AAA AAG ATA 814

815 GAC AAA TAG CAA ATA AGC ACT TGA ACA GGT GCT CAG CAT CGT TCG TTG 862

863 TCA GAG GAA TGC ACA CGA AAA CCG CAG CGA CAG CGA CTA GAA GAG CCA 910

911 GGT GCT GAG GAG GGT GCG GAG CCC CTG GAA CTC ACC CGT GCT GCT GAG 958

959 AAC ACA AAT GCT GCA TCC GCT TTG GAA AGC AGC TTG GGA GTT GCA TGT 1006

1007 GAA ATT CAG CAT TTA CCA CAC GGC CAG CAG TTC TGC TTT GGT TAT TCT 1054

1055 ACT CCA GAG TTT CCA CTG GGG GTC CTT TAT GAT TTC GTC TCT TCT ATC 1102

1103 ATT TTT TTG GTA TAG ATG GGG GTC TCG CTA TTT GGA TTA TTG TTG CAG 1150

1151 GCG TGT TTG GGG TTT TTG AGT AGT GGT AGT GTC TGA GGT CAG TCA GGG 1198

1199 TTG TTC TGG CCC CAG CAG GGC TCT TCG TAG CTT TTC CTG TGC AGG TGA 1246

1247 ACA AGC CTG CGG TTT CAC TTG TTT CTC TTA ACT TAA AGG AAC TGT TGT 1294

1295 TCC CAA GAG CAG TCT TGG GCT GAA CTT TCA AAT AAA ATG AGT TTC CTC 1342

1343 AGG GAG CTT CAG AGC TCT TTC CTT ATG GAC GGC CTC TCT CCC CAG GCT 1390

1391 GAT TTC TCT GCA CCA CCC TTC TGG GCA CTG GGT AAG ACA GCA GCC TCT 1438

1439 GAT CTT CTT GGC CTG GCT TTC CCA GCA TGG GTG CTC TAC CCT ACT GTT 1486

1487 TTA ACC TAG AAA GCC TGA ACT GTA TTT AAA ACT TGT GGT TTT TAA GGC 1534

1535 CAG GCA CAG TGG CTC ATG CCT GTA ATC CCA GCA CCT TGG GAA GCC AAG 1582

1583 GTG GGT GGA TCA CTT ATG GTC AGG AGT TCA AGA CCA GCC TGA CCA ACC 1630

1631 TGG TGA AAG CCT GTC TCT ACT AAA AAT ATA AAA ATA AGC CGG GCG TGG 1678

1679 TGG CAC ATG CCT GTA ATA CCA GCT ACC CAG GAA GCT GAG GCA GGA GAA 1726

1727 TTG CTT GAA CCC AGG AGG CGG AGG TTG CAG TGA GCC AAG ATG GCA CCA 1774

1775 CTG CAC TCC AGC CTG GGC GAC AGC GAG ACT CCA TAT AAA AAA AAA AAA 1822

1823 AAA AAA 1828

All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.

Claims (10)

1. isolating people's albumen with cancer suppressing function, it is characterized in that it comprises the polypeptide of the aminoacid sequence with the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:26, SEQ ID NO:29.

2. albumen as claimed in claim 1, it is characterized in that this proteic aminoacid sequence is selected from down group: SEQ ID NO:2, SEQIDNO:5, SEQIDNO:8, SEQIDNO:11, SEQIDNO:14, SEQIDNO:17, SEQIDNO:20, SEQ ID NO:26, SEQ ID NO:29.

3. isolating polynucleotide is characterized in that, it comprises a nucleotide sequence, and this nucleotide sequence is selected from down group:

(a) the proteic according to claim 1 polynucleotide of coding;

(b) with polynucleotide (a) complementary polynucleotide.

4. polynucleotide as claimed in claim 3 is characterized in that, the sequence of these polynucleotide is selected from down group:

The coding region sequence of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:30.

5. polynucleotide as claimed in claim 3 is characterized in that, the sequence of these polynucleotide is selected from down group:

The full length sequence of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:27, SEQ ID NO:30.

6. a carrier is characterized in that, it contains the described polynucleotide of claim 3.

7. a genetically engineered host cell is characterized in that, it is a kind of host cell that is selected from down group:

(a) host cell that transforms or transduce with the described carrier of claim 6;

(b) host cell that transforms or transduce with the described polynucleotide of claim 3.

8. the preparation method of the polypeptide of the people's protein-active with cancer suppressing function is characterized in that this method comprises:

(a) have under the proteic condition of people of cancer suppressing function suitable the expression, cultivate the described host cell of claim 7;

(b) from culture, isolate the polypeptide of people's protein-active with cancer suppressing function.

9. energy and the described people's protein-specific bonded antibody of claim 1 with cancer suppressing function.

10. a pharmaceutical composition is characterized in that, it contains the described albumen of claim 1 and the pharmaceutically acceptable carrier of safe and effective amount.